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1.1 BACKGROUND OF THE STUDY 
 
Access to medicine has two dimensions, that is; medicines need to be accessible as 
well as be affordable. Financial accessibility of medicines is one of the ongoing 
challenges faced by most developing countries.1 As such, access to medicine remains a 
challenge in the Southern African Development Community (SADC) region as most of 
these countries battle with three common killer diseases; Tuberculosis, Human 
Immunodeficiency Virus and Acquired Immune Deficiency Syndrome (HIV/AIDS), and 
Malaria. Most of the countries in this region depend on imported medicaments2 and 
although pharmaceutical companies attempt to make drugs affordable, most patented 
drugs are very pricy which often leads to affordability barriers.  
 
Since the 1980s, Intellectual Property Rights (IPRs) have been protected through a 
series of international conventions, namely; the Paris Convention for the Protection of 
Industrial Property (1883), the Berne Convention for the Protection of Literary and 
Artistic Works (1886) and the Washington Treaty on Intellectual Property on Integrated 
Circuits. It was only in 1995 that the World Trade Organisation (WTO) Agreement on 
the Trade Related Aspects of Intellectual Property (TRIPS)3 was formulated as a result 
of the Uruguay Round of negotiations. It is as a result of this Agreement that intellectual 
property rules that seek to inforce and protect IPRs especially patent rights were for the 
first time introduced into the multilateral trading system. Prior to the TRIPS there were 
                                                             
1  Lee, J & Hunt, P ‘Human Rights Responsibilities of Pharmaceutical Companies in Relation to Access to 
Medicines’ (2012) Journal of Law, Medicine & Ethics 225-226. 
2 These are substances used for medical treatment. See www.oxforddictionaries.com, accessed on 15 
April 2016. 
3 TRIPS: Agreement on Trade-Related Aspects of Intellectual Property Rights, Apr. 15, 1994, Marrakesh 
Agreement Establishing the World Trade Organization, Annex 1C, THE LEGAL TEXTS: THE 
RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS 320 (1999), 
1869 U.N.T.S. 299, 33 I.L.M. 1197 (1994) [hereinafter TRIPS Agreement]. 
2 
 
no international conventions that set out the minimum standards of patent protection.4 
This places a duty on WTO Members to modify their national legislation so as to 
conform to the minimum standards of intellectual property rights protection as set out by 
the TRIPS Agreement.5 Therefore, since ratification of the TRIPS is a compulsory pre-
requisite of WTO membership, any state seeking to access international markets 
governed by the WTO must incorporate the intellectual property rules mandated by 
TRIPS into their national legislation.6 It is for this reason that the TRIPS is considered 
the most important WTO Agreement that seeks to foster protection of IPRs. 
 
As such, the TRIPS Agreement increased patent protection at the expense of the 
States’ discretion to determine the duration of patent protection. It is undoubting that the 
patent system has advanced innovativeness and resulted in the development of 
medicines used to treat diseases that were once considered incurable. However, due to 
the TRIPS, states that ‘did not allow patent protection for pharmaceuticals or had limited 
protection to pharmaceuticals had to amend their legislation in order to become "TRIPS 
compliant".’7 
 
The pharmaceutical industry has exploited the patent system in a way to inhibit access 
to medicine by poorer countries by making these patented drugs unaffordable to them. 
For instance, it has been noted that the notorious practice by pharmaceutical 
companies of extending patent life spans past the compulsory 20 year time frame8 by 
filing for secondary patents is the leading cause of exorbitant drug prices.9 This practice 
elongates the exhaustion period of these patents therefore making it impossible for 
other pharmaceuticals to produce generic versions of the patented drugs. These current 
events highlight the need to prevent excessive intellectual property rights standards that 
                                                             
4 WTO and the TRIPS Agreement available at http://www.who.int/medicines/areas/policy/wto_trips/en/, 
accessed on 20 April 2016. 
5  Article 1.1 of the TRIPS Agreement. 
6  Article 65 ibid. 
7  Article 65(1) and (2) ibid. 
8  Article 33 ibid. 
9 These are subsequent patent rights based on modified compounds, dosages, formulations, medical 
uses of existing patented drugs. 
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may ultimately delay access to generic drugs.10 Countries such as India and Brazil have 
modified their patent laws to exclude from patentability new forms and uses of existing 
drugs so as to allow timely entrance of generic drugs in the market.11 
 
Secondly, the absence of the definition “invention” under the TRIPS Agreement has 
affected access to medicine. This is so because pharmaceuticals companies may 
acquire new licenses to drugs whose patent rights were almost exhausted by minimally 
improving the use of the drug and terming it as an inventive step. Drug patents are 
therefore extended without a clear improvement in their efficacy.12 These patents are 
usually known as ‘evergreen’ patents and are permissible under the TRIPS 
Agreement.13 
 
As an outcry to the over pricing of patented drugs, TRIPS flexibilities were included in 
the Agreement. These are provisions in the Agreement that permit governments to 
disregard in the enforcement of the Agreement for national concerns such as, but not 
limited to, health emergencies.14 Thus, developing countries may make use of TRIPS 
flexibilities to avoid patent protections and have access to generic drugs. It is on this 
basis that this thesis seeks to establish whether TRIPS flexibilities provide a legal basis 
for developing countries to evade the consequences of the patent system thus enabling 
them to have access to essential medicines.15 
 
                                                             
10 Amin, T & Kesselheim, AS’ Secondary Patenting of Branded Pharmaceuticals: A Case Study of How   
Patents on two HIV Drugs could be Extended for Decades’ (2012) 31(10) Health Affairs 2287. 
11 Committee on Development and Intellectual Property (CDIP) Study on Pharmaceutical Patents in Chile 
available at www.wipo.int/edocs/mdocs/mdocs/en/cdip_15/cdip_15_inf_2.docx,accessed on 20   
November 2016. 
12 Ndlovu, L ‘Lessons for the SADC from the Indian case of Novartis AG v Union of India’ (2015) 18(4) 
Potchefstroom Electronic Law Journal 785.  
13  Article 1 TRIPS Agreement. 
14 Sacco, SF A Comparative Study Of The Implementation In Zimbabwe And South Africa Of The 
International Law Rules That Allow Compulsory Licensing And Parallel Importation For HIV/AIDS 
Drugs (Unpublished LLM thesis, American University in Cairo, 2004) 21. 
15 Marks, ‘SP Access to Essential Medicines as a Component of the Right to Health’ (2009) Health: A 
Human Rights Perspective 85-88. 
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The TRIPS Agreement contains a number of flexibilities such as parallel importing16, 
government use,17 compulsory licensing,18 exhaustion of patent rights,19 exclusions 
from patentability,20 limitations on data protection21 and exceptions to patentability22 
designed to permit countries to access cheaper medicines. While the Agreement leaves 
the issue of interpretation and implementation at the states’ discretion, differentials in 
power and resources place limitations on how the TRIPS flexibilities can be utilized by 
developing countries.23 
 
The Doha Declaration on TRIPS and Public Health reaffirms IPRs but most importantly 
clarifies the scope of TRIPS and the position of developing countries. This was after 
developing countries raised concerns over developed countries using a narrow 
approach towards the TRIPS. The Doha Declaration therefore established that the 
TRIPS ought to be interpreted in a way that promotes access to medicine for all.24 It 
acknowledged the magnitude of health care problems faced by developing countries 
and as such exempted the Least Developed Countries (LDCs) from complying with the 
TRIPS until 1 January 2016.25 
 
There is an emerging phenomenon that the issue of access to medicine ought to be 
tackled from a human rights perspective. Access to medicine is a facet of the right to 
health and therefore countries need to deal away with existing obstacles in promoting 
access to medicines as a way of protecting the greater right to health.26 It has been 
                                                             
16  Article 6 of the TRIPS Agreement. 
17  Article 31(b) Ibid. 
18  Article 31 Ibid. 
19  Article 28 Ibid. 
20  Article 27 Ibid. 
21  Article 39.3 Ibid. 
22  Article 30 Ibid. 
23 Musungu, SF The Right to Health in the Global Economy: Reading Human Rights Obligations into the 
Patent Regime of the WTO-TRIPS Agreement (unpublished LLM thesis, Makerere University, 
(2001)10. 
24  Declaration on the TRIPS Agreement and Public Health, WTO Ministerial Conference, Fourth Session,  
Doha, adopted on 14 November 2001, WT/MIN(01)/DEC/2, at par 4.  
25 WTO document IP/C/25, available at http://www.wto.org/english/tratop_e/trips_e/art66_1_e.htm, 
accessed on 21 November 2016. 
26 Hestermeyer, H Human Rights and the WTO: The Case of Patents and Access to Medicines Oxford: 
Oxford University Press, (2007). Also read with Article 12 of the International Covenant on Economic, 
Social and Cultural Rights. 
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argued that the inability to access cheaper medicine is a threat to the right to health as 
drugs and therapies are an integral part of the realization of the right. The right to good 
health is a precondition to the enjoyment of all other rights27 and hence states are 
obligated to avert unreasonably high costs of medicines.28  
 
Access to medicine is not only based on the right to health but also the right to share in 
scientific advancements and its benefits.29 This entails that medical test data needs to 
be shared to enable production of generic drugs. This right based approach has been 
commended as it is founded on principles enshrined in human rights treaties which 
WTO Members are parties to and under which they voluntarily undertake to enforce 
trade rules and to respect and fulfil human rights.30 This presupposes that the right to 
health is a greater right compared to intellectual property rights which are merely 
temporary rights established to promote scientific inventions hence IPRs should never 
override the right to health.  
 
This position was re-affirmed in 2006 by General Comment No 17 in which the 
Committee affirmed the following; 
 
‘In contrast with human rights, intellectual property rights are generally of a 
temporary nature, and can be revoked, licensed or assigned to someone else. 
While under most intellectual property systems, intellectual property rights, with 
the exception of moral rights, may be allocated, limited in time and scope, traded, 
amended and even forfeited, human rights are timeless expressions of 
fundamental entitlements of the human person …’31 
 
                                                             
27 Socio economic rights such as the right to housing and the right to education cannot be enjoyed in the 
absence of good health. 
28 Chirwa, DM ‘The Right to Health in International Law: Its Implications for the Obligations of State and 
Non-State Actors in Ensuring Access to Essential Medicine’ (2003) 19 SAJHR 545-547. 
29 Article 15 (1) (b) International Covenant on Economic, Social and Cultural Rights (ICESCR). 
30 Benatar S, Brock G Global Health and Global Health Issues Cambridge: Cambridge University Press, 
(2011) 124-126. 
31 CESCR, General Comment No. 17 on the right of everyone to benefit from the protection of the moral 
and material interests resulting from any scientific, literary or artistic production of which he or she is 
the author, (2006) at para. 2. 
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However, the full enjoyment of the right to health remains indistinct due to obstacles in 
accessing cheaper medicines by most developing countries. The United Nations 
Millennium Development Goals (MDGs)32 emphasize the need to cooperate with 
pharmaceutical companies in order to improve availability of affordable essential 
medicines in developing countries.33 Goals number 4, 5 and 6 relate to health care in 
poor countries as they aim to reduce child mortality, improve maternal health and 
combat HIV/AIDS, malaria and other diseases respectively. According to the MDG 
reports, improved access to medicines in poor countries has led to the decline of most 
avoidable deaths.34 For instance deaths of children under 5 years of age as a result of 
measles has declined rapidly since 2000, from 544,200 deaths to 145,700 deaths in 
2013.35 Furthermore, despite that the rate of new HIV infections still remains high, more 
HIV positive people are able to live longer due to the increased use of antiretroviral 
therapy (ART).36 Since the introduction of ART in 1995, an estimate of 7.6 million 
deaths have been averted.37It is therefore evident that poor access to medicines 
continues to be the leading cause of deaths in most developing countries. This is 
because if essential medicines are not available in the public sector which usually 
provides medicines at a very low charge or no charge at all, patients will have to 







                                                             
32 These are the world’s 8 time-bound and quantified targets set at the UN Millennium Summit in 2000 for 
addressing extreme poverty in its many dimensions such as income poverty, lack of adequate 
healthcare, disease, lack of adequate shelter, education and environmental sustainability.See 
http://www.unmillenniumproject.org/goals/, accessed on 20 April 2016. 
33  Target 8e of the Millennium Development Goals available at https://www.oecd.org.dac, accessed on 
20 December 2016. 
34 Jamison, DT et al. Disease Control Priorities in Developing Countries 2 ed New York: Oxford University 
Press, (2006) 40. 
35 The Millennium Development Goals Report of 2015, available at www.un.org.2015_MDG_Report.pdf, 
accessed on 20 December 2016. 
36  Ibid. 
37  Ibid at 45-47. 
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1.2 PROBLEM STATEMENT 
 
Botswana is a landlocked country located in the South Western part of Africa bordering 
with Namibia, South Africa, Zambia and Zimbabwe. Due to its landlocked nature, it is 
highly reliant on alien commodities.38  
 
Due to Botswana’s small market size, its pharmaceutical industry till date does not 
manufacture pharmaceutical drugs and has a small number of registered 
pharmaceutical manufacturers.39 As a developing country, Botswana’s infant 
pharmaceutical industry is mostly involved in repackaging medicaments and distributing 
of the drugs.40 The government of Botswana therefore imports pharmaceutical 
medicaments and raw materials which are distributed to pharmacies for private 
consumption or for commercial repackaging and institutional uses.41 The country 
therefore remains reliant on importing pharmaceutical drugs in order to meet the needs 
of its people.  
 
Trade related IPRs may be the stepping stone in helping Botswana access cheaper 
generic drugs. In 2001, Botswana notified the WTO TRIPS Council of its intention to 
implement the minimum standards of IP protection according to the WTO TRIPS 
Agreement.42 Botswana as a developing country took advantage of these international 
trade law provisions and reviewed its IP laws to include these TRIPS flexibilities.43 
Botswana’s current legal and policy environment therefore makes it conducive to 
access cheaper medicines in the form of generics. 
Apart from other non-communicable diseases that the nation has to deal with, Botswana 
has one of the highest HIV infection rates in the world. As of 2014, Botswana had about 
                                                             
38 These are products imported from other countries. 
39 See https://www.frost.com/prod/servlet/report-brochure.pag?id=M438-01-00-00-00, accessed on 21 
November 2016. 
40  Ibid. 
41 See http://www.pharmexcil.com/v1/docs/Pharma_Industry_in_Botswana.pdf accessed on 24 April 
2016. 
42 WTO, Council for Trade-Related Aspects of Intellectual Property Rights Notification of Laws and 
Regulations under Article 63.2 TRIPS (2002). 
43 Guzik, B ‘Botswana’s Success in Balancing the Economics of HIV/AIDS with TRIPS Obligations and 
Human Rights’ (2006-2007) 4(2) Loyola University Chicago International Law Review 259. 
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390 000 people living with AIDS out of a total population of 1.2 million.44 In 2008 the 
government introduced a policy known as Botswana’s National Operational Plan for HIV 
and AIDS which was aimed at achieving Zero HIV infections in the years to come. This 
plan entails procuring and distributing critical medicines across all districts of 
Botswana.45 Botswana being a developing country, this policy has weighed heavily on 
the state’s finances. The HIV pandemic has had adverse impacts on the economy of 
Botswana. More so, due to lack of access to proper and adequate health care, the 
country’s mortality rate has sky rocketed leading to about 67 000 orphans due to AIDS 
related deaths.46 This creates an extra burden on the government to see to the needs of 
these orphaned children. 
 
As a result, in 2015, the Botswana government increased its state budget share to the 
pharmaceuticals sector with an allocation of BWP1.99billion as opposed to 
BWP1.82billion as was in the previous year.47 The Ministry of Health continues to 
receive the second largest state budget share.48 This goes to show the increasing need 
of the government to inject more money into the health sector in order to continue 
meeting the health needs of its people. Botswana currently uses patented drugs such 
as the Anti-Retro Viral (ARVs) and these patented drugs are becoming more expensive. 
It is therefore evident that the government needs to devise means of ensuring that it 
continues to scale up treatment and prevention within its financial capabilities. The use 
of generic drugs that are equivalent and interchangeable with the patented ones would 
be an important step to cutting the cost of drugs and therefore allowing the treatment of 
more people.49 
                                                             
44 UNAIDS available at http://www.unaids.org/en/regionscountries/countries/botswana, Accessed on 16 
March 2016. 
45 National Operational Plan for Scaling Up HIV Prevention in Botswana: 2008 – 2010 available at 
http://hivhealthclearinghouse.unesco.org/sites/default/files/resources/iiep_hiv_prevention_operational_
plan_botswana_apri_l_2008.pdf, accessed on 21 November 2016. 
46 UNAIDS available at http://www.unaids.org/en/regionscountries/countries/botswana, Accessed on 18 
March 2016. 
47  Matambo, OK 2015 Budget Speech available at 
http://www.gov.bw/global/portal%20team/2015%20budget%20speech%20by%20honourable%20o.pdf,
accessed on 9 March 2016.  
48  Ibid. 
49 Generic drugs are copies of brand-name (patented) drugs that have exactly the same dosage, intended 
use, effects, side effects, route of administration, risks, safety, and strength as the original drug. 
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Accordingly, this study seeks to establish the extent to which TRIPS flexibilities have 
been incorporated in Botswana’s national legislation. The study will further seek to 
examine the technical barriers in trade that are preventing Botswana from fully utilizing 
these TRIPS flexibilities in order to promote access to cheaper medicines.  
 
1.3 PRELIMINARY LITERATURE REVIEW 
 
In recent years, the increased protection of IPRs has become a controversial topic 
especially in developing countries as countries are aiming to intensify ways of promoting 
access to medicine but due to the monopoly pharmaceutical prices associated with 
these rights, treatment of diseases has become very expensive. There is an ongoing 
debate as to whether the right to health care and intellectual property rights conflict or 
coexist. Further, in the presence of a conflict which of the two rights should be given 
preference over the other. 
With the ongoing battle, Velasquez is of the opinion that developing countries are 
becoming victorious towards promoting access to medicine.50 He supports his argument 
by stating that the 2001 Doha Declaration was a stepping stone in dealing away with the 
misinterpretation of the TRIPS by most developed countries.51 He further argues that 
most developing countries can now import essential medicine from other Member 
States through the Paragraph 6 system.52 Velasquez is therefore of the view that even 
though the battle in promoting access to medicine is far from over, it is moving in the 
right direction.53 
The predicament of a country’s use of TRIPS flexibilities to access cheaper medicine is 
generally two-fold as it revolves around a country’s ability to acquire compulsory 
                                                                                                                                                                                                    
Available at http://www.medicinenet.com/script/main/art.asp?articlekey=46204, accessed on 25 April 
2016. 
50 Velasquez, German Bilateral Trade Agreements and Access to Essential Drugs, Bermudez Jorge, AZ 
and Oliveira-Auxiliadora, M, Intellectual Property in the Context of the WTO TRIPS Agreements: 
Challenges for Public Health, ENSP/ WHO – Oswaldo Cruz Foundation, 63 (2004). 
51 Ibid. 
52 Ibid. 
53 WIPO, Promoting Access to Medical Technologies and Innovation; Intersections between Public 
Health, Intellectual Property and Trade London: Book Now Ltd, (2013) 185. 
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licenses and to manufacture and export generic versions of patented drugs.54 The 
existence of IPRs has been the barrier of most developing countries to access cheaper 
generic drugs. As already discussed, most developing countries have infant 
pharmaceutical industries that make them unable to manufacture these generic drugs 
on their own. However, it is as a result of the increased patent protection offered by the 
TRIPS that pharmaceutical companies have become politically powerful as they 
consider the TRIPS as a launching pad for their ever expanding patents based  on the 
argument  that pharmaceuticals promote innovation. Ellen Hoen strongly points out that 
due to their exclusive nature, patent rights undoubtedly restrict access to medicines.55 
She argues that competition is the most proven effective way to bring drug prices down 
and this cannot be achieved where there is monopoly of positions in the pharmaceutical 
industry.56  
Most African countries believe that the standards set out in the TRIPS Agreement are 
the ceiling and not the floor of intellectual property rights protection.57 However as 
argued by Ellen Hoen, the TRIPS merely serve as a launching pad and there is nothing 
that prevents States from imposing stricter intellectual property protection in their 
national laws.58 The TRIPS merely sets out the minimum standards of protection that 
Member states are not to contravene.59 
Scholars such as Watal argue that TRIPS promotes the interests of global 
pharmaceutical companies by allowing them extend their control over their intellectual 
                                                             
54  Ndlovu, L Access to Medicines under the World Trade Organization TRIPS Agreement: A Comparative 
Study of Select SADC Countries (unpublished LLD thesis, University of South Africa, 2014) 12. 
55 Hoen, E TRIPS, Pharmaceutical Patents and Access to Essential Medicines: Seattle, Doha and 
Beyond Paris: National Agency for AIDS Research, (2003) 41. 
56  Hoen, E ‘TRIPS, Pharmaceutical Patents, and Access to Essential Medicines: A Long Way from 
Seattle to Doha’ (2002) 3 Chicago Journal of International Law 27-29. 
57  Mgbeoji, I ‘TRIPS and TRIPS Plus Impacts in Africa’ in Intellectual Property, Trade and Development: 
Strategies to Optimize Economic Development in a TRIPS-Plus Era Oxford: Oxford University Press, 
(2007) 269.  
58  Hoen, E ‘TRIPS, Pharmaceutical Patents, and Access to Essential Medicines: A Long Way from 
Seattle to Doha’ (2002) 3 Chicago Journal of International Law 32. 
59  Article 1 of the TRIPS Agreement states that Members are not obliged implement in their law more   
extensive protection than is required by the Agreement. 
11 
 
property.60 Grabowski emphasizes that increased patent protection is justifiable 
because the costs of innovation in the pharmaceutical industry are relatively high as 
compared to the costs of imitation so they ought to be patent protected.61 On the 
contrary, there is little evidence to prove that increased intellectual property protection 
incentivizes pharmaceutical innovation within developing countries. This may be 
supported by the CIPIH report which stated the following; 
 
‘It is also assumed that society at large will be able to benefit from present and 
future innovation. But where most consumers of health products are poor, as are 
the great majority in developing countries, the monopoly costs associated with 
patents can limit the affordability of patented health-care products required by 
poor people in the absence of other measures to reduce prices or increase 
funding. Thus the overall effect of intellectual property regimes is context-specific 
– the impact in a country such as India may differ from that in Thailand or in 
Ghana.’62 
 
Furthermore, pharmaceutical companies that own these patent rights are also resistant 
in permitting importation of these generic drugs.63 Pharmaceutical companies tend to 
abuse intellectual property rights in trade agreements thus undermining the very 
existence of patent flexibilities.64 Adusei further argues that one of the reasons most 
developing countries are unable to fully utilize TRIPS flexibilities is due to a poorly 
executed patent systems within these countries.65 He alludes to the fact that the same 
                                                             
60 Watal, J. (2000). Access to Essential Medicines in Developing Countries: Does the WTO TRIPS 
Agreement Hinder It? Science, Technology and Innovation Discussion Paper No. 8, Center for 
International Development, Harvard University, Cambridge, MA, USA. 
61 Grabowski, H ‘Patents, Innovation and Access to New Pharmaceuticals’ (2002) 5(4) Journal of 
International Economic Law 849. 
62  See Report of the Commission on Intellectual Property Rights, Innovation and Public Health (CIPIH), 
World Health Organization, Geneva, available at: 
http://www.who.int/intellectualproperty/documents/thereport/ENPublicHealthReport.pdf accessed on 
21 April 2016. 
63  Greene, W The Emergence of India’s Pharmaceutical Industry and Implications for the U.S Generic 
Drug Market Washington D.C: US International Trade Commission, (2007). 
64  Adusei, P ‘Exploiting Patent Regulatory “Flexibilities” to Promote Access to Antiretroviral Drugs in Sub-
Saharan Africa’ (2009) 9 University of Botswana Law Journal 3. 
65  Ibid at 4. 
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TRIPS Agreement that seems to promote access to medicine permits states to grant 
protection for medicinal test data.66 This is problematic as the TRIPS already grants a 
lengthy 20 year patent protection to pharmaceutical processes and products and 
therefore protecting medical test data creates some form of monopoly on the data which 
could have been utilized in the production of generic drugs. It could therefore be 
deduced that incorporating TRIPS flexibilities in a country’s intellectual property 
legislation cannot in itself promote access to medicine if the patent system itself is 
faulty. It is therefore clear that the battle of promoting access to medicine requires a 
balance of rights between the rights of the developing countries to access cheaper 
medicine and the protection of the pharmaceutical companies’ patent rights.67 Striking 
the balance between patent rights and promotion of public health requires a more 
comprehensive approach than merely having numerous flexibilities in the TRIPS 
Agreement promoting access to medicines.  
 
Pfumorodze also argues that most developing countries fail to fully utilize these 
flexibilities and this has been attributed to the social, economic and political status of the 
economy.68 He further argues that a country can only fully utilize TRIPS flexibilities if it 
has a relatively stable political and economic environment which is not the case for most 
developing countries.69 Pfumorodze made reference to Zimbabwe being the first 
developing country to issue a compulsory license in the post Doha period for 
manufacturing generic HIV/AIDS drugs by one of its pharmaceutical companies.70  
 
Furthermore, Sell identifies Free Trade Agreements (FTAs) as one of the barriers to 
access to medicine. She argues that these FTAs promote a strict standard of IPRs 
protection which denies developing countries the opportunity to pursue certain public 
                                                             
66  Article 39.3 of the TRIPS Agreement. 
67 Hanefeld, J ‘Patent Rights v Patient Rights: Intellectual Property, Pharmaceutical Companies and 
Access to Treatment for People Living with HIV/AIDS in Sub-Saharan Africa’ (2002) 72 Feminist 
Review 84-92.  
68 Pfumorodze, J ‘WTO TRIPS Agreement and Access to Medicines in Southern Africa’ (2011) 13 
University of Botswana Law Journal 99. 
69  Ibid at 102. 
70  Ibid at 101. 
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policy goals in the health sector.71 Sell argues that IP rights have been elevated to the 
status of master as opposed to servant when dealing with public policy matters.72 Roffe 
and Spennemann further substantiate this argument by stating that the growth of 
TRIPS-plus FTAs puts developing countries at risk of being unable to utilize the 
flexibilities granted to them through the TRIPS Agreement.73 This is so because most 
TRIPS-plus obligations aim at strengthening the position of pharmaceutical companies 
and are less geared towards promoting public health.74 This is worrisome as patent 
rights in their very own nature restrict developing countries’ access to medicine and 
therefore entering into FTAs may further jeopardize actual usage of TRIPS flexibilities.  
 
The above discussed literature therefore points to the fact that patent system is 
necessary and beneficial to promote innovation in the pharmaceutical industry. 
However, the very same patent system has proven to be a barrier in promoting access 
to medicine by poorer countries. Present literature has sought to identify the various 
reasons why developing countries are having challenges in fully utilizing the TRIPS 
flexibilities. However, the literature seems to analyze the position of developing 
countries as a whole without narrowing it down to country by country basis. This study 
therefore attempts to focus on Botswana specifically and then carry out a comparative 
analysis with other SADC countries. 
 
1.4 RESEARCH OBJECTIVES 
 
This study evaluated the extent to which SADC countries utilize TRIPS flexibilities in 
promoting access to medicine. The study attempted to answer the following specific 
research questions 
1. How did intellectual property come to be on the trade agenda? 
                                                             
71  Sell, SK ‘Trips-Plus Free Trade Agreements and Access to Medicines’ (2007) 28 Liverpool Law 
Review 57-58. 
72  Ibid at 58. 
73  Roffe, P & Spennemann, C ‘The impact of FTAs on public health policies and TRIPS flexibilities’ 
(2006) 1 (Nos. 1/2) International Journal of Intellectual Property Management 77. 
74  Ibid at 86. 
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2. How is the right to access to health care and intellectual property rights 
protected in Botswana? 
3. To what extent have TRIPS flexibilities been incorporated in SADC countries’ 
domestic legislations particularly Botswana to advance access to medicine? 
4. How do we ensure that developing countries make full use of the TRIPS 
flexibilities without falling foul of the basic tenets of intellectual property law?  
5. What legal and policy interventions need to be implemented to ensure that 
developing countries fully utilize TRIPS flexibilities?  
 
1.5 RESEARCH DESIGN 
 
This study was a qualitative non-empirical study. A qualitative study explores the 
richness and complexity inherent in a given research area rather than numbers and is 
most appropriate for exploratory studies.75 A qualitative study usually involves analysing 
information in an organized way which leads to the emergence of themes which helps 
the researcher unravel various aims and objectives of the research.76 This was suitable 
for this study as the researcher intended to delve into the complexities of the TRIPS 
flexibilities in promoting access to medicine in great depth so as to form a proper 
analysis. The research also involved constant comparison between the positions in the 
various SADC countries. 
 
In conducting the study, the researcher utilised both exploratory and analytical research 
methods. An exploratory study is mostly utilized where the researcher seeks to uncover 
information whose scope is unclear. It therefore seeks to reveals the dimensions of a 
particular phenomenon. In this study, the researcher attempted to establish the extent to 
which TRIPS flexibilities have been utilized by Botswana and other SADC countries.  
 
                                                             
75  Burns, N & Grove, SK Understanding Nursing Research Philadelphia: WB Saunders, (1999) 339. 
76 Polit, PD & Hungler, BP Essentials of nursing research. Methods, appraisal and utilization 4thed 
Philadelphia: Lippincott (1997) 239. 
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An analytical research method was used to identify any causal links between the factors 
that pertain to the research problem. In this study philosophical analysis was used to 
examine a proposition from various perspectives through the extensive exploration of 
literature. The study explored possible reasons why TRIPS flexibilities have not been 
fully utilized in Botswana and other SADC countries. This was so because from the 
existing literature it was observed that most developing countries have not fully utilized 
TRIPS flexibilities and hence the present study sought to discern the possible reasons 
for such.  
 
1.6 RESEARCH METHODOLOGY 
 
The study was an outright desk-top literature study. The researcher relied on primary 
and secondary sources of data. The study involved perusal of legislations of some 
SADC countries with particular emphasis on the laws of Botswana as well as 
International Treaties and Conventions that speak to human rights law and the right to 
health. The analysis of the intellectual Property Act of Botswana formed the bedrock of 
this research.   
The researcher made use of reliable internet sources in particular, the researcher 
consulted websites of International Organizations such as the World Health 
Organization (WTO) for purposes of accurate health related statistics needed for this 
research. The study to a large extent referred to textbooks and journal articles relating 
to the TRIPS Agreement and access to medicine particularly in the context of African 
developing countries. Such journal articles and textbooks were either be accessed from 
internet sources or from the library. 
  
1.7 STRUCTURE OF THESIS 
 
This study was organized into 5 chapters and is outlined as follows; 
Chapter One: Introduction. This chapter sets out the background of the research and a 
detailed outline of the research problem.  This chapter also sets out the aims of the 
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study together with the objectives the researcher sought to archive by the end of this 
research.  
Chapter Two: History of the development of Intellectual Property in International Trade. 
This chapter discusses the founding history of the General Agreement on Tariffs and 
Trade (GATT) and the World Trade Organisation (WTO). The TRIPS Agreements, Paris 
Convention together with the Berne Convention were discussed in great details together 
with their relevance to this study.  
Chapter Three: The human rights and intellectual property framework of Botswana. The 
aim was to identify how intellectual property laws and human rights are protected in the 
country. The chapter evaluated how national regulatory bodies in Botswana protect the 
right to health care and intellectual property rights. The chapter also assessed the level 
of protection that is afforded to non-governmental organizations (NGOs) as well as 
government authorities that deal with the issue of access to medicine and the right to 
health in general.  
Chapter Four: Comparison of Botswana’s intellectual property legislation with other 
SADC countries such as South Africa and Zimbabwe. The aim was to discern the extent 
to which these other SADC countries have incorporated TRIPS flexibilities in their 
national legislation. Relevant case law was discussed under this chapter. 
The final chapter, Chapter Five comprised of the recommendations and conclusion of 










Intellectual property rights (IPRs) have always existed but resided primarily within the 
domestic sphere.77 The protection of IPRs at an international level has been 
characterised with different phases of development. The initial phase is characterised 
with the absence of the international protection of IPRs. As such, it was only towards 
the end of the 19th century that states began to demonstrate more prominent 
enthusiasm towards the likelihood of worldwide co-operation on intellectual property 
matters. This was mostly portrayed through the formation of unions by European 
countries for the protection of literary and artistic works and industrial property.78 
Formerly, international protection of intellectual property was only found in bilateral 
commercial agreements involving mainly European countries.  
 
Over the years there has been a remarkable creation of different international 
instruments that deal with intellectual property. These instruments were dissimilar in as 
far as the extent of protection of IPRs that was afforded. This eventually led to the 
formation of the Paris Convention for the Protection of Industrial Property, 188379 and 
the Berne Convention for the Protection of Literary and Artistic Works, 1886.80 These 
                                                             
77 Tully, LD ‘Prospects for Progress: The TRIPS Agreement and Developing Countries after the DOHA 
Conference’ (2003) 26(1) B.C. Int’l & Comp.L.Rev 131. 
78 Onguglo, BF ‘Developing Countries and Unilateral Trade Preferences in the New International Trading 
System’, available at https://www.wto.org/english/tratop_e/devel_e/sem01_e/ongugl_e.doc, accessed 
on 15 August 2016. 
79  Paris Convention for the Protection of Industrial Property of March 20, 1883 as revised at Brussels on 
December 14, 1900, at Washington on June 2, 1911, at The Hague on November 6, 1925, at London 
on June 2, 1934, at Lisbon on October 31, 1958, and at Stockholm on July 14, 1967, and as amended 
on October 2, 1979 [hereinafter Paris Convention]. 
80  Berne Convention for the Protection of Literary and Artistic Works of September 9, 1886, completed at 
Paris on May 4, 1896, revised at Berlin on November 12, 1908, completed at Berne on March 20, 
18 
 
are the oldest agreements in as far as international protection of intellectual property 
rights is concerned. The final development phase was the formation of the Agreement 
on Trade-Related Aspects of Intellectual Property Rights, 1994 (the TRIPS 
Agreement).81 
 
This chapter seeks to discuss the history of IPRs in international trade. The chapter will 
therefore include a detailed discussion of various international agreements and the level 
of intellectual property rights protection that is accorded by each of the agreements. The 
chapter will also identify the possible setbacks of these agreements as far as protection 
of intellectual property rights is concerned.  
 
2.2 THE PARIS CONVENTION FOR THE PROTECTION OF INDUSTRIAL 
PROPERTY 1883 
 
This was the first and most important international instrument that dealt with protection 
of intellectual property, particularly, the protection of patents on industrial innovations. 
Its main aim was to harmonize patent laws and regulations as stipulated by various 
countries.82 The adoption of the Paris Convention was preceded by the International 
Conference on patent rights held in Vienna, Austria in 1873.83  The Congress of Vienna 
led in turn to an International Congress on Industrial Property, convened at Paris in 
1878.84 At the latter Congress, States sought to establish an international uniform patent 
application process. Prior to the Paris Convention, individuals wanting to protect their 
inventions in several countries needed to simultaneously file patent applications in all 
                                                                                                                                                                                                    
1914, revised at Rome on June 2, 1928, at Brussels on June 26, 1948, at Stockholm on July 14, 1967, 
and at Paris on July 24, 1971, and amended on September 28, 1979 [hereinafter Berne Convention]. 
81 Drahos, P ‘The Universality of Intellectual Property Rights: Origins and Development’, available at 
http://www.wipo.int/edocs/mdocs/tk/en/wipo_unhchr_ip_pnl_98/wipo_unhchr_ip_pnl_98_1.pdf, 
accessed on 29 June 2016. 
82 Correa, CM ‘An Agenda for Patent Reform and Harmonization for Developing Countries’ A Paper 
prepared for the Bellagio Dialogue on “Intellectual Property and Sustainable Development: Revising 
the agenda in a new context” , International Center for Trade and Sustainable Development (ICTSD), 
24 – 28 September 2005, Bellagio, Italy. 
83 Reiss, SM ‘Commentary on the Paris Convention for the Protection of Industrial Property’, Lex- IP 
available at http://www.lex-ip.com/Paris.pdf, accessed on 3 August 2016. 
84 WIPO, Introduction to Intellectual Property, Theory and Practice Kluwer Academy: Kluwer Law 




such countries in order to avoid the loss of eligibility of patent protection in such 
countries.85 It is for this reason that the French Government circulated a draft 
convention setting out an international unification for the protection of industrial 
property. The 1880 International Conference in Paris adopted this draft convention of 
which many of its provisions underlie the current Paris Convention.86  
 
The Paris Convention therefore deals with cross boarder patenting and simplifies the 
patent application process. Developing countries have always been reluctant to ratify 
patent treaties particularly the Paris Convention due to the fear that no technical 
assistance would be afforded to developing countries in as far as implementing treaty 
obligations is concerned.87 However, States that are not members to the Paris 
Convention but are signatories to the WTO are obliged to comply with the provisions of 
the Paris Convention from the date of their application to the WTO.88 This is also 
stipulated under Article 2 of the TRIPS Agreement which requires all WTO members to 
comply with Articles 1 through 12 and 19 of the Paris Convention. The above stated 
Articles state as follows; 
 
‘Industrial property shall be understood in the broadest sense and shall apply not 
only to industry and commerce proper, but likewise to agricultural and extractive 
industries and to all manufactured or natural products…patents shall include the 
various kinds of industrial patents recognized by the laws of the countries of the 
Union, such as patents of importation, patents of improvement, patents and 
certificates of addition, etc.’89 
 
                                                             
85 See http://www.adamsadams.com/wp-content/uploads/2015/12/Patent-Brochure.pdf, accessed on 21 
December 2016. 
86 Reiss, SM ‘Commentary on the Paris Convention for the Protection of Industrial Property’, Lex- IP 
available at http://www.lex-ip.com/Paris.pdf, accessed on 3 August 2016. 
87 Correa, CM & Yusuf AA (ed) Intellectual Property and International Trade: The TRIPS Agreement 
Amsterdam: Kluwer Law International, (2008) at 36. 
88 Reiss, SM ‘Commentary on the Paris Convention for the Protection of Industrial Property’, Lex- IP 
available at http://www.lex-ip.com/Paris.pdf, accessed on 4 August 2016. 
89  Article 1 of the Paris Convention. 
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‘Each country of the Union undertakes to establish a special industrial property 
service and a central office for the communication to the public of patents, utility 
models, industrial designs, and trademarks.’90 
 
‘It is understood that the countries of the Union reserve the right to make 
separately between themselves special agreements for the protection of 
industrial property, in so far as these agreements do not contravene the 
provisions of this Convention.’91 
 
One of the setbacks of this Convention was its failure to outline minimum standards for 
patent protection to which its Members must adhere.92 The scope and level of the 
intellectual property rights protection Member States were expected to implement under 
the Convention were left to domestic legislation and courts to develop.  This therefore 
did not in any way harmonize the standards of intellectual property protection in 
international trade as standards were subject to states’ discretion.93 The lack of 
provisions setting out the minimum standards of IPRs and mandating the enforcement 
of those rights has been argued to be the basis for the establishment of the TRIPS 
Agreement which will be discussed later.94 
 
2.3 BERNE CONVENTION FOR THE PROTECTION OF LITERARY AND ARTISTIC 
WORKS 1886 
 
The Berne Convention was the oldest international convention in the area of copyright 
and still forms the cornerstone of international copyright law. The Agreement was 
prompted by the need to bring uniformity to the number of bilateral agreements that 
existed at that time. Interestingly, the Berne Convention was successful in outlining the 
minimum standards of copyright protection. For example, Article 2(7) of the Convention 
                                                             
90  Article 12 of the Paris Convention. 
91  Article 19 of the Paris Convention. 
92 Tully, LD ‘Prospects for Progress: The TRIPS Agreement and Developing Countries after the DOHA 
Conference’ (2003) 26(1) B.C. Int’l & Comp.L.Rev 132. 
93  Article 19 of the Paris Convention.  
94 Reiss, SM ‘Commentary on the Paris Convention for the Protection of Industrial Property’, Lex- IP 
available at http://www.lex-ip.com/Paris.pdf, accessed on 3 August 2016.  
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provides that Member States are free to decide the extent and conditions under which 
works of applied art and industrial designs are protected in their national laws. 
According to Article 20 of the Convention, “States are permitted to enter into special 
agreements, among themselves, which grant authors more protection than those 
granted by the Convention or other provisions which do not contradict the provisions of 
the Convention.” However, the Convention failed to establish extensive legal remedies 
which could be enforced by the copyright holders against the copyright infringers. 
 
Conclusively, the Paris and Berne Conventions steered in harmonizing international 
cooperation in intellectual property. In 1893, the Paris and Berne Conventions became 
part of the United International Bureaux for the Protection of Intellectual Property also 
known as Bureaux Internationaux Réunis pour la Protection de la Propriété Intellectuelle 
(BIRPI) which later evolved into the World Intellectual Property Organisation (WIPO) 
which will be discussed later.95  
 
Linked to the developments in IP was the idea to revive the world economy, thus in the 
wake of the World War II an organisation called the International Trade Organization 
(ITO) was formed whose mandate was to regulate international trade.96 The ITO was 
thus intended to perform the role of a global trade ministry. This organisation was 
championed by the United States together with its allies but became a “still born” due to 
the US Congress withholding its ratification of the Havana Charter. The Havana Charter 
was the agreement that provided for the establishment of the ITO.97 The failure of the 
ITO marked the first casualty of the post-war international political environment.  
 
2.4 THE GENERAL AGREEMENT ON TARIFFS AND TRADE (GATT) 1947 
 
In 1947, after the failure of the ITO, about 23 negotiating states led primarily by the 
United Kingdom, United States (US) and Canada converged in Geneva, Switzerland in 
                                                             
95 Curtis, JM ‘Intellectual Property Rights and International Trade: An Overview’ (No.3 May 2012),CIGI 
papers available at  https://www.cigionline.org/sites/default/files/no.3.pdf,accessed on 17 June 2016. 
96  Ibid. 
97 Bossche, P The Origins of the WTO. The Law and Policy of the World Trade Organization: Text, Cases 
and Materials Cambridge: Cambridge University Press, (2005) 14. 
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order to establish a post war world trading system.98 The General Agreement on Tariffs 
and Trade (GATT) came about at the end of World War II. After World War I &II, the 
international trading system was in shambles. The goal therefore was to create an 
agreement that would ensure postwar stability and avoid a repeat of the mistakes of the 
past. States had begun to conclude unfair trade arrangements for their own political 
agendas. This led to the destruction of the multilateral trading system that existed prior 
to World War I.99The GATT was therefore established as the custodian and enforcer of 
free trade in the multilateral trading system. As such, the GATT was more of a contract 
to which states were Contracting Parties rather than an organization in which they were 
Member States. 
 
The GATT was characterized by 8 rounds of negotiations addressing various trade 
issues starting with the Geneva Round in 1947 ending with the Uruguay round which 
ran from 1986-1994.100 The first rounds of GATT negotiations mostly dealt with tariff 
reductions. Countries participating in these negotiations were primarily focused on 
reducing tariff trade barriers across the board which they succeeded in substantially. 
The Uruguay Round was responsible for ending the GATT era in 1994 by ushering in 
the WTO. Similarly, it was only during the Uruguay round of negotiations that intellectual 
property matters were tabled for discussion under the GATT.101  
 
Intellectual property rights were not completely foreign to the GATT before they were 
tabled for negotiation during the Uruguay Round. However, the GATT did not expressly 
oblige States to accord any level of protection towards intellectual property rights.102 
The founding Agreement under Article XX(d) allowed Contracting States to enforce 
intellectual property rights in a manner that would normally be inconsistent with the 
                                                             
98   Irwin, DA et al. The Genesis of the GATT Cambridge: Cambridge University Press, (2009)1. 
99   Ibid at 7-9. 
100 GATT rounds; Geneva Round 1947, Annency Round 1949, Torquay Round 1951, Geneva Round 
1955-56, Dillon Round 1960-62, Kennedy Round 1964-67, Tokyo Round 1973-79, Uruguay Round 
1986-94. 
101 WTO website ‘The GATT Years: From Havana to Marrakesh’, available at www.wto.org/english/the 
wto_e/whatis_e/tif_e/fact4_e.htm, accessed on 17 August 2016. 
102 Chung-Lui, K & Sun, H ‘A Universal Copyright Fund: A New Way to Bridge the Copyright Divide’ 
(2006) 1(2) National Taiwan University Law Review 38-40. 
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GATT provided such measures are not used as a disguised barrier to trade. The Article 
stipulates that: 
 
‘Subject to the requirement that such measures are not applied in a manner 
which would constitute a means of arbitrary or unjustifiable discrimination 
between countries where the same conditions prevail, or a disguised restriction 
on international trade, nothing in this Agreement shall be construed to prevent 
the adoption or enforcement by any contracting party of measures 
… 
(d) necessary to secure compliance with laws or regulations which are not 
inconsistent with the provisions of this Agreement, including those relating to … 
the protection of patents, trademarks and copyrights, and the prevention of 
deceptive practices…’103 
 
The Agreement does not make any special dispensation for the protection of intellectual 
property rights. Article XX(d) of the GATT therefore did not compel Contracting States to 
adopt such measures but rather gave a leeway when the need to enforce intellectual 
property rights arose.104  
 
Furthermore, in 1967, a diplomatic conference was held in Stockholm at which all the 
clauses of all existing multilateral treaties administered by BIRPI were revised and the 
Convention Establishing the World Intellectual Property Organization (WIPO) was 
signed.105 The Convention came into effect in 1970. WIPO as a specialized agency of 
the United Nations is responsible for the protection of intellectual property rights across 
the globe by ensuring states’ cooperation of treaties administered under this 
organization. However the formation of a new organisation was looming which was 
envisioned to govern all aspects of Trade, including IP.106  
                                                             
103  General Agreement on Tariffs and Trade 1947 (GATT 1947), 55 U.N.T.S. 194. 
104  Hartridge,D & Subramanian A ‘Intellectual Property Rights: The Issues in GATT’ (1989) 22 Vanderbilt 
Journal of Transitional Law 901. 
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2.5 THE WORLD TRADE ORGANISATION (WTO) 
 
Upon the failure of the ITO, countries fell back on the GATT which became the centre-
piece of the multilateral trading system. Consequently, this led to the number of GATT 
contracting parties multiplying. The WTO came into force on 1 January 1995 as a result 
of the eight rounds of multilateral trade negotiations that were hosted by the GATT. The 
Uruguay round which marked the final GATT round marked the birth of the WTO. The 
formation of the WTO coincided with the end of the Cold War.107 
 
The WTO is founded on very important principles that govern the multilateral trading 
system such as that of non-discrimination, open and predictable trade by reducing trade 
barriers, transparency and providing special treatment for less-developed Members. 
Due to stunted economic growth, most developing countries cannot fully enjoy the 
benefits of trade liberalization. There is need for the WTO to make efforts aimed at 
ensuring that less-developed countries equally participate in the multilateral trading 
system as developed countries. Also, the principle of transparency as provided for 
under Article X of the GATT requires Member States to make publicly available all 
relevant trade regulations before application and to notify the WTO and other Members 
of its actions.108 The principle of non-discrimination has two facets; Most Favoured 
Nation (MFN) principle and the principle of National Treatment. The MFN principle 
subject to exceptions prohibits Member States from discriminating between their trading 
partners whereas the National Treatment principle dictates that locally-produced goods 
and imported goods should be treated equally.109 
 
 
                                                             
107 VanGrasstek, C The History and Future of the World Trade Organization Geneva: Atar Roto Presse 
SA, (2013) 10-15. 
108 Matsushita, M ‘Basic Principles of the WTO and the Role of Competition Policy’ (2004) 3(2) 
Washington University Global Studies Law Review 366-368. 
109 Ya Qin, J ‘Defining Non Discrimination under the Law of the World Trade Organization’ (2005) 23 
Boston University International Law Journal 216-222. 
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2.5.1 Organizational Structure of the WTO 
 
The Ministerial Conference is the highest decision making body of the WTO.110 It is 
usually composed of Ministers of Trade of the Members of the WTO. Below the 
Ministerial Conference lies the General Council. The General Council is considered as 
the engine of the WTO as it responsible for the day to day running of the WTO. It also 
sometimes assumes the powers of the Ministerial Council when latter is not in 
operation.111 The General Council also acts as the Trade Policy Review Body and the 
Dispute Settlement Body (DSB).112 At the next level is the Council for Trade in Goods, 
the Council for Trade in Services and the Council for Trade-Related Aspects of 
Intellectual Property Rights (TRIPS). The Council for TRIPS is an important body for 
purposes of this research as ‘it is charged with the monitoring of WTO Members’ 
compliance with their obligations under TRIPS Agreement.’113 It therefore serves as a 
forum for consultation between Member States regarding the interpretation of TRIPS 
provisions. Consequently the Council for TRIPS may in advance resolve impending 
disputes between States without the need to seek recourse from the DSB.114 At the 
bottom of the organizational structure lies specialized committees such as 
the Committee on Balance-of-Payments, the Committee on Trade and Development, 
Restrictions and the Committee on Budget, Finance and Administration115 followed by 
the Director-General and the Secretariat which operate on a purely administrative basis.  
 
2.6 THE TRIPS AGREEMENT 
 
Prior to the Uruguay Round of negotiations, there was little protection of intellectual 
property rights in the international realm. The GATT considered intellectual property 
matters to be “internal” matters that resonated between States in their private dealings. 
                                                             
110  WTO, Understanding the WTO-Organization Chart, available at https://www.wto.org>tif_e>org2_e,  
accessed on 21 December 2016. 
111   Ibid. 
112   Article IV:(2)-(4) of the WTO Agreement. 
113   Article IV:(5) of the WTO Agreement. 
114  Malbon, J & Lawson, C Interpreting and Implementing the TRIPS Agreement: Is it fair? Edward Elgar 
Publishing, (2008) 53. 
115   Article IV:(7) of the WTO Agreement. 
26 
 
The primary thrust of GATT rules of relevance was to ensure that intellectual property 
laws do not discriminate against or between imported goods.116 For this reason, the 
TRIPS Agreement has been a major step in international trade as far as the protection 
of IPRs is concerned. It sets the minimum standards for the protection of IPRs relating 
to patents, copyright and trade secrets particularly those related to innovation and 
technology transfer, and public health issues.117 As noted earlier, these standards 
mostly emanate from obligations emanating from the Berne, Paris, Rome and 
Washington Conventions. 
The genesis of the TRIPS Agreement can be traced as far as the case of Punta del 
Este mandate in September 1986.118 This Ministerial Meeting formed the genesis of the 
Uruguay Round of trade talks. Its main aim was to clarify the GATT provisions and ‘to 
develop a multilateral framework of rules and principles dealing with international trade 
in counterfeit goods.’ The TRIPS was therefore not the main focus of attention in Punta 
del Este but the US was the driver behind intellectual property being included as a 
negotiating issue.119 This is so because at the end of the Tokyo Round of negotiations, 
the US became concerned at the level at which there was inadequate and ineffective 
protection of intellectual property abroad thus discouraging innovativeness and 
damaging the US industry at large.120 These sentiments were also shared by other 
industrialized countries who were of the opinion that increased intellectual property 
rights protection would lead to greater economic gains as it would drastically reduce 
piracy.121 
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Then again, developing countries were of the view that IPR protection campaign by the 
US government was solely for the benefit of its industries and the international IPR 
regime was intended to promote the interests of Western businesses and not those of 
developing countries.122 Furthermore, developing countries were of the view that IPRs 
would restrict free flow of information which was responsible for facilitating development 
in the pharmaceutical sector. These developing countries were also enjoying 
unprecedented freedom to exploit intellectual property for their own economic 
development.123 Increased intellectual property protection would therefore hamper the 
economic development of these countries as they freely use such information. As such, 
developing countries vehemently resisted the idea of including IPR protection as a topic 
of discussion under the multilateral trade negotiations.124 
There are several other issues that led to the issue of IPRs being tabled during the 
Uruguay round of negotiations. The formation of WIPO whose mandate was to 
coordinate intellectual property rights laws across the multilateral system led to 
developed countries becoming frustrated at the progress of intellectual property rights 
protection under the WIPO. One of the issues of concern was the fact that many 
developing countries had not joined the WIPO and therefore such countries did not 
have any obligations under international law to implement IPRs in their domestic 
laws.125   
Secondly, developed countries were dissatisfied with the level of protection that was 
afforded to intellectual property rights under the WIPO as the level of intellectual 
property rights protection under the WIPO was weaker than what most developed 
countries had established domestically.126 The rules under WIPO also did not cover a 
wide range of intellectual property areas such as software which developed countries 
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sought to protect.127 The Uruguay round of negotiations therefore gave developed 
countries an opportunity to negotiate higher levels of intellectual property rights 
protection in the international realm. Hence, since developing countries did not join 
WIPO due to their lack of interest in implementing intellectual property rights in their 
domestic laws, it would have also naturally followed that developing countries would be 
reluctant in joining the WTO’s intellectual property agreement (TRIPS Agreement). 
It was only in December 1988 at a mid-term review meeting held in Montreal where 
some developing countries, especially those considered to be market based economies 
and export-oriented began to move their positions in TRIPS matters. At the time of its 
conclusion, the WTO TRIPS Agreement was the most far-reaching international treaty 
ever negotiated in the area of intellectual property rights.128 The Agreement identifies 
and defines seven categories of intellectual property and sets out the international 
minimum standards of protection they ought to be accorded. It identifies the main 
elements of protection for each category, the rights to be conferred and permissible 
exceptions to those rights.  These categories include; patents, copyright, industrial 
designs, trade secrets, integrated circuit designs, trademarks and geographical 
indications.129 The TRIPS Agreement therefore not only ensures intellectual property 
rights are protected but also ensures that legal remedies are available for rights holders. 
It further effectively linked intellectual property rights with international trade whilst at the 
same time balancing between the need to promote and protect innovations with the 
need to other promote socio-economic rights.130 Article 7 of the Agreement stipulates 
that; 
‘the protection and enforcement of intellectual property rights should contribute to 
the promotion of technological innovation and to the transfer and dissemination 
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of technology ... and in a manner conducive to social and economic welfare, and 
to a balance of rights and obligations.’131 
Unlike the shortfalls outlined in the Paris and Berne Convention, the TRIPS Agreement 
therefore addressed problems of inadequate international protection of intellectual 
property rights which often resulted in disparities in the levels of protection of intellectual 
property across the world. Furthermore, the TRIPS Agreement provided effective 
enforcement of the various intellectual property rights and acceding to submit such 
disputes to the WTO Dispute Settlement Understanding (DSU).132  
 
2.6.1 Post TRIPS 
 
The TRIPS Agreement being an agreement administered under the WTO marked the 
beginning of an evolution in as far as globalizing of intellectual property rights is 
concerned.133 Article 1.1 of the TRIPS Agreement places a duty on WTO Members to 
modify their national legislation so as to conform to the minimum standards of 
intellectual property rights protection as set out by the TRIPS Agreement. 
Consequently, ratification of TRIPS is a compulsory pre-requisite of WTO membership 
and it is for this reason that the TRIPS is considered the most important WTO 
Agreement that seeks to foster protection of IPRs. This therefore has a harmonizing 
effect on IPRs in the international realm by setting out the detailed minimum standards 
IPRs.  
 
The post-TRIPS era has been a period in which states have engaged in the task of 
national implementation of their obligations under the TRIPS Agreement. Furthermore, 
the monitoring by the Council for TRIPS through the enforcement of intellectual property 
obligations has fostered the protection of these rights particularly patent rights. More so, 
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the TRIPS Agreement brought diverse impacts on developing countries based on the 
extent to which these countries domestically championed for IPRs protection prior to 
becoming WTO Members. To most developing countries, the establishment of the 
TRIPS Agreement entailed a great deal of reform to their domestic legislation in as far 
as intellectual property was concerned. However, developing countries were granted up 
to 5 years of transitional period to implement TRIPS obligations while Least Developed 
Countries (LDCs) were granted a 10 year transitional period which could be extended 
upon request.134  
As earlier discussed in this chapter, developing countries were reluctant to sign the 
TRIPS Agreement due to fear of the economic implications as the Agreement would 
forestall access to new technologies leading to higher prices especially in 
pharmaceuticals. In order to address these concerns, the TRIPS gives Member States 
flexibilities in implanting their domestic intellectual property regimes. These flexibilities 
allow states to disregard TRIPS obligations for national concerns such as health issues. 
 
2.7 DEVELOPMENT OF INTELLECTUAL PROPERTY IN FREE TRADE 
AGREEMENTS (FTAs)135 
 
While many believed that the introduction of the TRIPS Agreement sufficiently placated 
intellectual property rights, the Agreement could be said to have become a stepladder in 
achieving stronger IPRs. Over the years, the world has witnessed an increase in the 
formation of FTAs which address a variety of matters but at the same time contain 
intellectual property provisions which are agreed on between Member States in 
exchange for trade preferences and other advantages. These FTAs which at times 
involve agriculture seek to implement intellectual property standards set out in the 
TRIPS Agreement. These agreements are known as TRIPS- plus FTAs.  
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Member States are then required by these agreements to implement the ‘bare minimum 
standards’ of the TRIPS which signify a growing trend in the inclusion of intellectual 
property matters in FTAs.136 This often results in domestic laws that exceed the 
minimum standards outlined by the TRIPS Agreement.137 Consequently, while 
developing countries are still struggling to conform to the standards set out by the 
TRIPS, developed countries continue to strengthen intellectual property rights through 
FTAs. This is a challenge to most developing countries as higher standards of 
intellectual property protection may restrict their access to cheaper medicines.  
There has been a significant broadening of patentability in FTAs. These agreements 
introduce provisions that allow patenting of new forms and new uses of known 
substances, which create the threat of “ever-greening” of pharmaceutical patents.138 
Ever greening in the pharmaceutical industry is described as instances where a 
pharmaceutical company patents a ‘new invention’ which is merely a slight modification 
of an old drug.139 However, even though the pharmaceutical companies aver that the 
generic versions of the old version can still be produced, the creation of the new version 
counteracts and disrepute the effectiveness of the old version thereby compelling 
doctors to prescribe the improved version.140 
Extension of patent duration is also a TRIPS plus provision that prolongs the patent 
monopoly and further restrains the entrance of generic competitors to the markets. 
These FTAs are usually drafted in ways that ensure swift integration of developing 
countries into multilateral IP regimes. Thus, developing countries are being obliged to 
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conform to multilateral standards in Conventions to which they are not a party to and/or 
to ratify multilateral treaties.141  
However, due to the increased preference of free trade agreements over multilateral 
agreements, developing countries are not hesitant to trade off intellectual property rights 
in order to gain market access in these free trade agreements. This is so because 
developing countries perceive free trade agreements to be more beneficial compared to 
the pyrrhic victories of multilateralism.142 TRIPS- plus provisions therefore have the 
potential of limiting the flexibilities available to mostly developing countries. Under 
normal circumstances free trade agreements should not compromise on the core TRIPS 
flexibilities. This is so because such derogation may be construed to be incompatible 
with the object and purpose of the TRIPS Agreement. The Preamble encourages the 
need for Member States …  
 
‘to take into account the need to promote effective and adequate protection of 
intellectual property rights, while recognizing the underlying public policy 
objectives of national systems for the protection of intellectual property, including 
developmental and technological objectives.’  
 
Conclusively, there is growing evidence that TRIPS-plus provisions may adversely limit 





The negotiation and development of intellectual property rights has always existed in 
the international realm but existed independent to international trade negotiations. The 
development of intellectual property rights in international trade has become 
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increasingly a multidimensional process as it entails harmonizing a diversity of 
international organizations, free trade agreements, national laws and most importantly 
international agreements such as the TRIPS Agreement. The TRIPS agreement is the 
major highlight as far as the protection of intellectual property rights is concerned. 
Issues of intellectual property rights went from being issues of national consideration to 
having a status of a core obligation in the international trading system. The integration 
between intellectual property rights and international trade has called for a solid and 
harmonized intellectual property rights framework in order to ensure adequate 
protection of these rights and effective remedies internationally.  
Thus, chapter three will address how these intellectual property rights are protected in 
Botswana. The chapter will begin off with a discussion on the existence of the right to 
health care in Botswana’s Bill of Rights. Furthermore, the chapter will include an 
analysis on how Botswana’s IP legislations seek to protect IP rights. The chapter will 
conclude with a discussion on the various Non- Governmental Organizations that seek 











The crux to protecting health rights such as access to medicine is the incorporation of 
the right to health care in the Bill of Rights or national legislation of a given country. 
Where countries have such national legal frameworks where the Constitution is the 
supreme law of the land like Botswana, then any subsidiary laws that seek to violate 
such constitutional rights would be unconstitutional and unenforceable. This creates an 
obligation on the state to ensure that the right to health care is upheld and protected at 
all times. The state is also expected to take reasonable steps in developing an 
administrative and legal framework that is conducive for the actualization of the right.143 
In general, the realization of socio-economic rights has been cumbersome particularly 
their inclusion as justiciable rights in the Constitution. These groups of rights are subject 
to state resources due to the fact that they are usually classified as rights granting 
“access” to certain social benefits, rather than as direct rights to the social benefits in 
question.144 Socio- economic rights can be classified into two categories; qualified and 
unqualified rights. Qualified socio-economic rights are those rights that are inherently 
limited due to the availability of state resources whereas unqualified rights do not make 
reference to available state resources reasonable measures and progressive 
realization. The right to health care is classified as an unqualified socio-economic 
right.145 However, due to limited state resources, unqualified rights may also be 
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limited.146 This position was reinforced by the South African courts in the case of 
Soobramoney147 where it was stated that; 
‘Given this lack of resources and the significant demands on them ..., an 
unqualified obligation to meet these needs would not presently be capable of 
being fulfilled.’148 
This chapter therefore seeks to determine whether the right to access to health care is 
protected in Botswana. Further, the chapter also seeks to establish the extent to which 
intellectual property rights are protected in Botswana. Thus, the chapter will firstly 
review Botswana’s position on the right to health care before addressing the protection 
of intellectual property rights. 
 
3.2 THE RIGHT TO HEALTH CARE AND ACCESS TO MEDICINE IN BOTSWANA 
 
Unlike South Africa which will be discussed later, the Constitution of Botswana has no 
express provision to the right to health care. However, Section 4 of the Constitution149 
provides for the right to life. It stipulates that; 
 
‘no person shall be deprived of their life intentionally unless done in execution of 
a sentence of a Court in respect of an offence under the law in force in Botswana 
of which they have been convicted.’ 
 
The Constitution however allows for other rights to be disregarded for the protection of 
public health. Section 8(1)(a)(i) of the Constitution permits one’s property to be 
compulsorily taken possession of where the acquisition is necessary for the protection 
of public health. Similarly, Section 9 justifies searching of another’s property or entering 
on such premises without the owner’s consent where it is reasonably required in the 
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interest of public health.150 Botswana therefore has a very conservative Constitution in 
as far as promoting the right to health care is concerned. The Constitution of Botswana 
does make specific reference to access to medicines. It does not expressly provide for 
the right to health care but however contains provisions that limit other rights such as 
the right to protection from deprivation of property and the right to privacy of one’s 
property in the interest of public health. 
 
3.3 PUBLIC HEALTH: INTERNATIONAL REGIONAL AND NATIONAL LEGAL 
FRAMEWORKS 
It is worthwhile considering whether the protection of ‘public health’ is a facet of the 
greater right to health care under international instruments protecting the right to health. 
It is worth noting that International human rights instruments have not been consistent in 
the formulation of this right to health. For example, the Constitution of the World Health 
Organization (WHO) defines health as ‘a state of complete physical, mental and social 
well-being and not merely the absence of disease or infirmity.’151  
On the other hand, Article 25 of the United Nations' Universal Declaration of Human 
Rights (UDHR)152 states that ‘Everyone has the right to a standard of living adequate for 
the health and well-being of himself and of his family, including food, clothing, housing 
and medical care and necessary social services.’ Article 12 of the International 
Covenant on Economic, Social and Cultural Rights (ICESCR)153 considers the right to 
adequate standards of living as a component of the right to health. This is in line with 
the definition of health under the WHO which includes social well-being as an aspect of 
health. It states as follows; 
‘Everyone has the right to a standard of living adequate for the health and 
wellbeing of himself and of his family, including food, clothing, housing and 
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medical care and necessary social services, and the right to security in the event 
of unemployment, sickness, disability, widowhood, old age or other lack of 
livelihood in circumstances beyond his control (emphasis added).’  
This entails that under Article 12 of the ICESCR, the right to health is not confined to 
health care alone but extends to conditions pertinent to good health such as housing, a 
healthy environment and access to safe and potable water. This is important bearing in 
mind that promoting the right to health through ensuring access to medicine cannot be 
achieved in isolation to all other underlying conditions.154 The Constitution of Botswana 
can therefore be said to be more focused on the social well-being aspect of the right to 
health as compared to the others. 
 
Notably, the right to health as outlined under Article 25 of the UDHR entails that people 
should have access to medical care. Access to essential medicine is a pre-requisite to 
proper medical care in any given country.  
 
3.3.1 South Africa 
 
In comparison to the South African position, the starting point would be Section 11 of 
the Constitution155 which guarantees everyone the right to life. Not only is the right to life 
protected under the Constitution, the right to health care is also provided for under 
Sections 27, 28 and 35 of the Constitution. Section 27(1)(a) states that; 
 
‘Everyone has the right to have access to health care services, including 
reproductive health care... and no one can be denied emergency medical 
treatment.’156  
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Section 28(1)(c) grants every child the right to basic health care services, while section 
35(2)(e) provides for ‘adequate medical treatment’ for detainees and prisoners at the 
State's expense.  
Not only does the South African Constitution guarantee the right to health care, the 
Medicines and Related Substances Act157 under Section 22F also promotes the 
substitution of patented drugs for generic medicines as a way of promoting access to 
cheaper essential medicines. It creates a duty on the dispensing pharmacist ‘to inform 
the person visiting the pharmacy of the benefits of the substitution of a branded 
medicine for an “interchangeable multi-source medicine” and shall in the case of a 
substitution…dispense an interchangeable multi-source medicine instead of the 
medicine prescribed by a medical practitioner…unless expressly forbidden to do so.’158  
Section 22F describes generic medicines as “interchangeable multi-source medicines”. 
The term “interchangeable multi-source medicines” has been defined as ‘medicines that 
contain the same active substances which are identical in strength or concentration, 
dosage form and route of administration and meet the same or comparable standards, 
which comply with the requirements for therapeutic equivalence as prescribed.’159 
The above Section further prohibits such substitution where the ‘retail price of the 
interchangeable multi-source medicine is higher than that of the prescribed branded 
medicine.’160 This is so because the purpose of the Section is to afford cheaper 
alternative drugs to patients where the branded medicine is costly. Having more 
expensive generic drugs forgoes the true purpose of their creation which is to help 
alleviate the strain of expensive drugs on the consumer. Other countries like Zimbabwe 
(as discussed below) and Botswana have similar pieces of legislation neither of the two 
pieces of legislation make reference to the use of generic drugs as in the South African 
Act. 
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3.3.2 Zimbabwe  
 
In Zimbabwe, the right to health-care is provided for under Section 76 of the 
Constitution of Zimbabwe161. It states that; 
 
‘Every citizen and permanent resident of Zimbabwe has the right to have access 
to basic health-care services…no person may be refused emergency medical 
treatment in any health-care institution…and the state must take reasonable 
legislative and other measures to achieve the realization of this right.’  
The absence of the right to health care under Botswana’s Bill of Rights is very flawed. 
This is so because General Comment 14 of the ESCR (Economic, Social and Cultural 
Rights) Committee162 illuminates that ‘health is a fundamental human right 
indispensable for the exercise of other human rights.’ Although these comments are not 
legally binding on states, they serve as authoritative expert advice on the interpretation 
of the rights enshrined in the ICESCR. This essentially entails that a state should first 
guarantee its citizens the right to health care as the bedrock right before other 
subsidiary rights could be achieved.163   
Human rights are an important empowering tool as they enable vulnerable individuals to 
assert themselves against powerful entities such as the government. The absence of 
the right to health care in the Constitution of Botswana strips off its citizens with the 
most important fighting tool in advocating for better health care services. Furthermore, 
the provision of the right to health care also serves as a yardstick that social delivery 
structures use in achieving the desired goal and measuring its outcome. That being the 
case, what criteria does the government of Botswana use in assessing whether 
adequate health care services are being rendered to its citizens.164 
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Others may argue that since the Constitution of Botswana does not expressly provide 
for the right to health care particularly access to medicine, then the right in question is 
not justiciable.165 It has however been counter argued that absence of codification of the 
right in a country’s national law does not bar its adjudication and enforcement by the 
domestic courts of law. Lack of constitutional protection therefore burdens the courts 
and other non-state actors with the onerous task of enforcing these indistinct rights.166 
The right to life as guaranteed by Section 4 of the Constitution has corollaries on the 
right to health care if interpreted extensively. Courts and other bodies may simply argue 
that the state therefore has a duty to take provide adequate health care services so as 
to prevent death  as a means of protecting the greater right to life. 
 
3.4 NON-GOVERNMENTAL ORGANIZATIONS’ INTERVENTION IN PROMOTING 
PROPER HEALTH CARE 
 
The protection of health care rights by legislation alone is insufficient. There is need for 
non-state actors to ensure such legislation is respected. Despite the absence of the 
right to health care in Botswana, it has quite a number of non-governmental 
organizations (NGOs) that aim at protecting and promoting health interests of the 
citizens particularly the vulnerable ones. These NGOs do exist to provide health and 
social services to the community as a way of promoting proper health care as provided 
for in international charters to which Botswana is a signatory of.  NGOs may therefore 
be regarded as valuable partners in promoting better health care services. Discussed 
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Ditshwanelo (established in 1993) also known as the Botswana Centre for Human 
Rights is the most prominent and only non-governmental organization (NGO) that is 
aimed at promoting and protecting all aspects of human rights in Botswana. There exist 
other NGOs dealing with human rights but such organizations are rights-focused for 
instance dealing with children’s rights. The Organization is tasked with raising public 
awareness of the various human rights that are provided for in the Constitution of 
Botswana.167 They also advocate for reforms in governmental policies, practices and 
laws that are a threat to human rights. In pursuit of protecting human rights, the 
organization provides paralegal services to aggrieved citizens who cannot afford legal 
representation. The Organization also works in partnership with other rights-focused 
organizations in Botswana to educate, mediate on issues of human rights especially to 
the marginalized and disempowered population.168 
 
Ditshwanelo could therefore be described as the voice of the nation when dealing with 
matters of human rights infringement. Its existence as a non-governmental organization 
makes it independent and not subject to manipulation by governmental bodies or 




The Botswana Network of AIDS Services Organization (BONASO) is yet another 
organization that seeks to facilitate the environment for HIV/AIDS NGOs. It therefore 
serves as the umbrella body that coordinates all other NGOs that deal with HIV/AIDS 
issues. This in turns strengthens the capacity of these NGOs in Botswana as it serves 
as a mouth piece for all its members.169  
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3.4.3 The Botswana Network on Ethics, Law and HIV/AIDS (BONELA)170 
 
This is a non-governmental organization that seeks to integrate a human rights 
approach to the fight against HIV/AIDS as way of promoting the greater right to health. 
The organization is vested with a human rights monitoring (HRM) unit whose 
responsibility is to investigate human rights violations and to develop strategies in 
addressing HIV/AIDS human rights violation. The HRM also probes into all 
unprogressive and oppressive laws and policies.171 Although the organization seeks to 
monitor all types of human rights violation such as the right to education and personal 
liberty (gay rights), its main focus is on the right to health particularly in relation to 
HIV/AIDS.172 
 
3.4.4 BONEPWA (BOTSWANA NETWORK OF PEOPLE LIVING WITH HIV/AIDS) 
 
BONEPWA is an organization of people living with HIV/AIDS in Botswana. Its main 
objective is to facilitate the formation of support groups for people living with HIV/AIDS 
in Botswana. This includes the formation of projects that seek to ensure that people 
living with HIV/AIDS have access to proper health care and other needs peculiar to their 
condition.173 
 
3.4.5 The Holy Cross Hospice 
This is a non-governmental organization that seeks to provide additional palliative care 
to persons suffering from life threatening illnesses especially those coming from poor 
communities of the country. Their palliative services are meant to improve the quality of 
life and well-being of the patients by providing better medical care as they are mostly 
unable to afford proper medical care on their own. This has been achieved by their 
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hospice facilities which are sustained by raising funds in various ways so as to 
remunerate personnel that are responsible for carrying out the objectives. Furthermore, 
in order to ensure that the hospice program of care is living up to its objectives, the 
organization also provides essential medicines to the patients.174 This is an important 
milestone in ensuring people living with life threatening diseases have access to proper 
medical care. The organization works very closely with the Ministry of Health of 
Botswana and health training institutions such as the medical and nursing schools for 
additional technical assistance.175 
  
3.5 PROTECTION OF INTELLECTUAL PROPERTY RIGHTS IN BOTSWANA 
 
Botswana is a signatory to a number of international agreements that deal with 
intellectual property rights such as Paris Convention of 1998.176 Botswana has only two 
pieces of legislation that deal with intellectual property rights, that is; the Copyright and 
Neighbouring Rights Act177 and the Industrial Property Act.178 According to the Industrial 
Property Act, the provisions of any international agreement dealing with intellectual 
property rights to which Botswana is a party of shall be applicable under the Act in the 
absence of any reservations made in relation to those treaties.179 Botswana is also a 
Member of the ARIPO (African Regional Intellectual Property Organization) which is an 
inter-governmental organization that deals with intellectual property matters in Africa. 
The ARIPO which is also a signatory to the Patent Cooperation Treaty was established 
in 1976 by the Lusaka Agreement as result of a diplomatic conference held in Zambia 
championed by the World Intellectual Property Organisation (WIPO) and the UN 
Economic Commission for Africa (UNECA). The Harare Protocol which was 
subsequently adopted by the Administrative Council of the ARIPO in December 1982 
entrusted ARIPO with the task of granting and registering of patents on behalf of 
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Member States.180 Botswana only became a member of the ARIPO on 6 February 1985. 
The above treaties assist Botswana in constructing a framework for the protecting of 
intellectual property rights in the country. This is so because the treaties acceded to 
require Botswana to implement the minimum set out intellectual property standards in 
their national legislation. This is important particularly in the era where there is an 
increase in innovativeness in the pharmaceutical industry and hence the need to protect 
such inventions.181 
The Copyright and Neighbouring Rights Act deals with the protection of the rights of 
artists, authors and creators, as well as the protection of their literary and artistic work 
such as musical works, drawings, poems and films.182 The most relevant piece of 
legislation for the purposes of this research is the Industrial Property Act. The 
classifications of intellectual property rights protected under this Act are trademarks,183 
industrial designs,184 utility models185 and patents186.  
The Industrial Property Act provides for the registration of trademarks and patents. 
Botswana has domesticated in its national laws the Harare Protocol which regulates 
patent filings in ARIPO. This is an intellectual property protective mode as it gives valid 
patent protection to applicants seeking to obtain a patent via an ARIPO application. 
Patent protection in Botswana is therefore available by way of a national filing (in 
Botswana) or via an ARIPO application designating Botswana.187  
Under the national filing system, a patent application is filed with the Registrar of Marks, 
Patents and Designs accompanied with a petition that a patent be granted.188 The 
Registrar then examines the application to determine if such application complies with 
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the requirements of the Act.189 According to Section 8 of the Act, “an invention is 
patentable if it is new, involves an inventive step and is capable of industrial 
application.” Where the Registrar is satisfied that these requirements have been fulfilled, 
a patent is to be granted to the applicant and a patent certificate is issued.190 
Under the Harare protocol, the applicant designates all other ARIPO member states to 
which the application applies.191 The applicant therefore need not make subsequent 
duplicate applications in all other countries. Only one application is sufficient by 
designating the Member states where protection is required.192Upon receipt of the 
patent application, the ARIPO office examines whether the object of the application is 
patentable.193 According to Section 10(a) of the Harare Protocol, ‘a patent shall be 
granted if its new, involves an inventive step and capable of industrial application.’ Once 
all the requirements for patentability have been satisfied copies of the application are 
sent to all designated member states. The designated states are to respond to the 
notification within six months and inform the ARIPO office if the patent if granted will 
have effect in its territory.194 Upon the expiration of the six months period, the Office 
shall grant the patent which shall have effect even in designated States which did not 
respond to the notification.195 Furthermore, Section 29 of the Industrial Property Act 
makes specific reference to patents granted under the Harare protocol. It states that; 
“a patent granted by ARIPO by virtue of the Harare Protocol under which 
Botswana was designated, shall have the same effect and enjoy the same 
protection in Botswana as a patent granted under this Act unless the Registrar 
communicates… to ARIPO to state that patent shall have no effect in Botswana.” 
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It is also worth noting that Botswana is also a member of the Patent Cooperation Treaty 
(PCT).196 ARIPO Member states automatically become members of the PCT. The PCT 
patent application process comprises of two phases which are the international and the 
regional phase.  Under the international phase, the applicant files an application with the 
Receiving Office (RO). Once the PCT application has been filed, all contracting states of 
the PCT are automatically designated. According to Article 11(3) of the PCT treaty, ‘any 
international application … accorded an international filing date shall have the effect of a 
regular national application in each designated State as of the international filing date, 
which date shall be considered to be the actual filing date in each designated State.’ 
Since Botswana is a member of the PCT and ARIPO which is also party to the PCT, 
once a PCT application is filed, Botswana may be designated when the application 
reaches the ARIPO regional phase of the PCT application and such patent if granted is 
known as a regional patent.197 Members may however file for reservation to be 
excluded from the automatic designation. It is worth highlighting that the PCT does not 
grant patents. The PCT procedure merely simplifies the procedure of filling patent 
applications in multiple PCT Member states. The PCT application may therefore be 
granted or rejected based on the applicable national law of each designated state. 
Before the Industrial Property Act of 2010 came into effect, Botswana had not 
domesticated any Patent Cooperation Treaty provisions into its national intellectual 
property laws. Therefore, although it was possible for a pharmaceutical company to file 
a PCT application designating Botswana, it was not clear whether enforceable rights 
could be obtained by such patent being granted on PCT national phase filing in 
Botswana. The Industrial Property Act under Part III now provides for PCT 
applications.198 Section 37 of the Act seeks to establish the effects of designating 
Botswana in an international application. It stipulates that; 
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‘An international application designating Botswana shall be treated as an 
application for a patent filed under this Act and shall have as its filing date the 
international filing date accorded under the Patent Cooperation Treaty.’ 
The Act under Section 41 further provides that ‘when processing an international 
application the Patent Cooperation Treaty, its Regulations and the administrative 
instructions issued under it shall, in the event of any conflict, prevail over this Act and its 
regulations.’ 
 
3.6 THE COMPANIES AND INTELLECTUAL PROPERTY AUTHORITY 
 
The Companies and Intellectual Property Authority (CIPA) is the formal tool for 
intellectual property rights management in Botswana. The CIPA Botswana is a 
parastatal under the Ministry of Trade and Industry established by the Companies and 
Intellectual Property Authority Act.199 This body was formerly a governmental 
department and was known as the Registrar of Companies and Intellectual Property 
(ROCIP). The body is tasked with the registration of trade marks, industrial designs and 
the granting of patent certificates.200 Most importantly, the body is responsible for the 
protection of intellectual property rights by administering the Industrial Property Act201 
and the Copyright and Neighboring Rights Act.202 CIPA may therefore be regarded as 
the custodian of intellectual property rights in Botswana as one of its responsibilities 
save for the registration of patents is combating copyright infringement and piracy in 
Botswana.  
 
Furthermore, the transition of this body from a governmental body to a parastatal was 
an important step in ensuring its independence thus improving its efficiency. Such 
privatization has reduced the possible threat of government manipulation in carrying out 
its task of protecting intellectual property rights. Protection of intellectual property rights 
particularly patent rights encourages innovation in the pharmaceutical industry. This 
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eventually leads to an increase in the discovery and development of medicines to cure 
various diseases. The patent system has therefore worked well for pharmaceutical 
companies as they are enthused to discover new medicines since they are guaranteed 




The Constitution of Botswana has no express provision on the right to health care. 
However, other rights enshrined in its Bill of Rights may be disregarded for the 
protection of public health. The absence of the right to health care under Botswana’s Bill 
of Rights is very flawed as good health forms the bedrock of the enjoyment of all other 
subsidiary rights. This has created an onerous task on NGOs in Botswana in enforcing 
and protecting this indistinct right. Botswana could therefore learn from South Africa and 
Zimbabwe by amending its Constitution to include the right to health care particularly 
access to medicine. More so, Botswana could amend its Drugs and Related 
Substances Act to include provisions similar to those under South Africa’s Medicines 
and Related Substances Act encouraging the substitution of patented drugs for generic 
versions as a way of promoting access to cheaper medicine. Conclusively, there is 
inadequate protection of these rights in Botswana. The government needs to do more in 
protecting both the right to health care and intellectual property rights thus ultimately 
making them more justiciable. 
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BOTSWANA’S ACTUAL USAGE OF TRIPS FLEXIBILITIES IN 




In the year 2000, it was reported that over 2 million people in sub-Saharan Africa died 
of AIDS.204 AIDS therefore is the leading threat to human security in the region and this 
is mostly attributed to the lack of or shortage of Antiretroviral drugs (ARVs) supply in 
these countries.205 Thus, improving access to medicines particularly ARVs in this 
region would drastically reduce the death toll. The Trade-Related Aspects of 
Intellectual Property Rights Agreement (TRIPS)206 contains a number of flexibilities 
aimed at promoting and improving access to medicines. Khor argues that the adoption 
of the Doha Declaration on the TRIPS Agreement and Public Health at the Doha 
Ministerial Conference in 2001, emphasized that ‘developing countries should make full 
use of the flexibilities to take public health measures, including compulsory licensing 
and parallel importation, which can make medicines more accessible and 
affordable.’207 More so the author argues that least developed countries should also 
make use of the extra flexibilities afforded to them under the same Declaration.208 
However, despite the appeals of Doha, developing countries have been lackluster in 
taking advantage of this call.  
Thus, this chapter seeks to discuss the extent to which the flexibilities contained in the 
TRIPS have been incorporated in Botswana’s domestic intellectual property legislation 
and the extent of the actual usage of each of the flexibilities in promoting access to 
essential medicines. This chapter shall further explore the reasons for Botswana’s 
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failure to make full use of the TRIPS flexibilities to promote access to medicine in 
comparison to Zimbabwe and South Africa.  
 




In light of the controversy surrounding  access to medicines and patents the following 
exceptions will be explored; exceptions to patent rights, compulsory licensing, 
limitations on data protection, the Paragraph 6 system, parallel importing, exclusions 
from patentability and public non-commercial use of patents. 
 
i. Exclusions from Patentability  
 
The TRIPS Agreement under Article 27.1 provides for the basic test of patentability. It 
provides that ‘patents shall be available for any inventions provided they are new, 
involve an inventive step and are capable of industrial application.’ More so, Article 27 
thereon goes to provide for exceptions to patentability209 which is an important flexibility 
in promoting access to medicine as they facilitate the dissemination of technology in the 
pharmaceutical sector. The aforementioned Article stipulates that; 
‘Members may exclude from patentability inter alia one which is necessary to 
protect human life and diagnostic, therapeutic and surgical methods for the 
treatment of humans’ 
This is a mostly forgotten TRIPS flexibility as emphasis is placed on the flexibilities that 
are acceptable under the TRIPS Agreement and not the issue of the grant of the 
pharmaceutical patent itself.210The Industrial Property Act211 of Botswana has similar 
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provisions dealing with exclusions from patentability. Particularly, Section 8 of the Act 
provides that; 
‘an invention shall be patentable if it is new, involves an inventive step and is 
capable of industrial application.’ 
The wording of Section 8 of the Industrial Property Act is similar to that of Article 27.1 of 
the TRIPS Agreement. Furthermore, Section 9 of the Act212 provides for matters that are 
excluded from patent protection even if they may be regarded as inventions. The 
relevant exclusion for purposes of this discussion is the exclusion of methods used for 
the treatment of the human body by therapy or surgery as well as all diagnostic 
methods except products used in any such methods.213  
 
ii. Compulsory Licensing 
 
A compulsory license may be defined as a license issued by a government authority to 
a pharmaceutical company which is not the patent owner authorizing the use or 
manufacturing of a patent- protected drug without the consent of the right holder.214 
Patent rights enable a patentee to prevent third parties from exploiting his intervention. 
Under compulsory licensing, reasons such as that of public health enable a third party 
to exploit such a patent without prior authorization from the patentee.215 Under the 
TRIPS Agreement, compulsory licenses are worded differently. The Agreement uses 
the wording ‘use without authorization of the right holder’216when referring to 
compulsory licensing.  
More so, Article 31 of the TRIPS Agreement deals with the granting of a compulsory 
license to a third party. It provides that compulsory licensing may only be issued after 
the person seeking to acquire it had tried to negotiate with the right holder to obtain a 
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voluntary license.217 The right holder is entitled to adequate remuneration upon granting 
of the compulsory license.218 Compulsory licensing may therefore be utilized by local 
pharmaceutical companies to manufacture generic versions of patented drugs where 
the patented drugs are costly. The granting of compulsory licenses in Botswana is 
provided for under Section 31 of the Industrial Property Act. It stipulates that;  
‘A Minister may without the consent of the patentee authorize a Government 
agency, or other person to exploit the patented invention on the payment of 
adequate remuneration to the patentee where it is in the public interest to do so 
for purposes of nutrition and health.’219 
Despite the fact that compulsory licensing may seem to be an effective way to ensure 
access to medicine by enabling generic production of drugs, there are limitations to its 
effectiveness in Botswana. It should be noted that the TRIPS Agreement under Article 
31(f) provides that drugs manufactured under a compulsory license shall be 
predominantly for use in the domestic market of the country granting the license and not 
for export. Botswana has no domestic pharmaceutical manufacturing capacity and 
therefore cannot use this flexibility to avoid the costs associated with patent recognition 
of pharmaceuticals. The requirement of Article 31(f) is what led to the developing world 
pressuring other WTO Members to devise a solution to this barrier.220 
As such, in 2001, the Doha Ministerial Conference as a way of solving this 
problem suggested a waiver of this export restriction to allow developing countries 
unable to manufacture the pharmaceuticals to manufacture generic drugs from a foreign 
pharmaceutical company.221 This waiver was approved in 2003 by the decision of the 
WTO General Council and led to the establishment of the Paragraph 6 system.222 Of 
interest, compulsory licensing on its own did little to increase access to medicines in 
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countries with little or no pharmaceutical manufacturing capacity and the Paragraph 6 
system therefore provided for derogations from obligations set out under Article 31 of 
the TRIPS Agreement.223 It waived under certain circumstances the requirements that; 
1) compulsory licenses are only to be granted for the purposes of predominantly 
supplying the domestic market224 and  
2) Members are to pay adequate remuneration to the right holder once is 
compulsory license is granted.225  
 
The Paragraph 6 system enables a WTO Member to import or export drugs 
manufactured under compulsory licensing amongst other Members of a Regional Trade 
Agreement (RTA) on condition that at least half the membership of consists of LDCs.226 
LDCs are automatically eligible to import under the Paragraph 6 system while the 
declaration also lists 23 developed countries that may not make use of this waiver to 
import generic drugs.227 Consequently, Member countries such as Botswana that do not 
have their own pharmaceutical manufacturing capability can issue a compulsory license 
so that another country manufactures generic drugs on their behalf. 
This waiver was incorporated in the TRIPS Agreement under Article 31bis.  Article 31bis 
therefore amends Article 31(f) of the TRIPS Agreement by permitting foreign 
pharmaceutical manufacturers to export drugs to developing countries under 
compulsory licensing. The Paragraph 6 system allows for compulsory licenses to be 
issued in countries for the manufacture of generic drugs provided they are exported to 
principally LDCs.228 The purpose of this derogation was to address the concerns of 
developing countries that due to their small markets they are unable to effectively attract 
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generic suppliers to produce medicines for their countries and this made it mandatory 
for other WTO members to export to LDCs.229  
Furthermore, the Paragraph 6 system sought to avoid double remuneration to the 
patentee when a compulsory license is granted.230 Where a patented drug exists in both 
the importing and exporting countries, Article 31(h) of the TRIPS Agreement requires 
that adequate remuneration be paid in both countries to the patentee. Paragraph 6 
system derogates from this obligation and provides for payment of remuneration only by 
the exporting Member.231 Developing countries already lack financial resources to 
acquire most medicines and therefore it was rather punitive to require them to also pay 
the patentee remuneration when importing such medicines.  
In order for a country to rely on the Paragraph 6 system, the potential exporting country 
must amend its domestic legislation to enable the production and export of generic 
medicines under compulsory licenses.232 This can create a potential barrier for some 
developing countries to make use of this waiver under Article 31bis of the TRIPS 
Agreement. This is because this may be a difficult task to implement on the part of the 
potential exporting country. Furthermore, Paragraph 6 system dictates that for a country 
to import such drugs, they must be an illegible importing Member.233An importing 
illegible Member has been defined as; 
‘any LDC member or any member that has notified the TRIPS council of its 
intention to use the system set out in Article 31bis…as an importer.’234 
Such notice must also set out the names of the drugs and quantity needed.235 This 
creates a burdensome expectation on a developing country like Botswana that is 
already facing a health crisis.  
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Botswana’s Industrial Property Act236 provides that exploitation of patented invention for 
compulsory licensing purposes shall be for the supply of domestic market in Botswana 
except where Article 31bis applies. Furthermore, Section 32(4) also provides that; 
‘where a compulsory license is granted, and remuneration has been paid in the 
exporting country, the obligation to pay remuneration to import that product into 
Botswana shall not apply.’ 
Thus, as argued above, since Botswana is a developing country that has no 
pharmaceutical manufacturing capacity and has incorporated the provision of the 
Paragraph 6 system, it may make use of this waiver to import generic drugs from other 
countries under compulsory licensing.  
 
iii. Public non Commercial Use of Patents (Government Use) 
 
This is the right conferred on a government to use a patented product without the 
consent of the patentee.237 Article 31 of the TRIPS Agreement covers both non 
voluntary use of patents by compulsory licensing and government use. Article 31(b) of 
the TRIPS therefore recognizes non-commercial use of patented products by the 
government without the consent of the patentee. It does not define what amounts to 
non-commercial use but it should be understood to mean for non-profit purposes. The 
distinction between government use and compulsory licensing lies in the use of the 
patent.238 Under government use, the use of the patent is limited to non-commercial 
purposes whereas compulsory licensing may cover private and commercial use.239 
In respect of this, Section 32 of the Industrial Property Act of Botswana provides for  
‘…importation of patented products such as generic pharmaceutical products 
from any legitimate alternative foreign source without the approval of the 
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patentee where it is in the public interest to do so for purposes of nutrition and 
health…or the market for the patented product is not being supplied in sufficient 
quantities or on reasonable terms in relation to market demand as long as it is 
done solely for non-commercial purposes.’ 
Under this flexibility, the government needs to inform the patentee of the intention to 
override the patent. This makes it easier to utilize because the procedure involved is not 
as cumbersome as that of compulsory licensing.240 
 
iv. Parallel Importing 
 
‘Parallel importing is the import and resale in a country without the consent of the patent 
holder of a patented product that has been legitimately put on the market of the 
exporting country.’241 The disparity between market prices of pharmaceuticals in various 
countries is the economic driver of parallel importing. Parallel importing expands the 
competition faced by the manufacturers and benefits consumers through lower prices of 
drugs.242 In reference to access to medicine, this essentially means that medicines may 
be imported from countries where they are sold at a lower price if the same medicine is 
available in the importing country but at a higher price. 
Article 28 of the TRIPS Agreement confers certain rights on the patentee, one of which 
is the right preventing third parties from importing patented products without the 
patentee’s consent.243 However, patent rights are not absolute and may be limited by 
the “exhaustion” doctrine. Parallel importing arises as a consequence of the doctrine of 
exhaustion of rights. The doctrine of exhaustion stipulates that once a patented product 
has been marketed either by the patentee or by other with his/her consent the patent 
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rights of commercial exploitation over this given product can no longer be exercised.244 
This means that once the patented drug is launched into the market, the patent holder 
has no right to control its subsequent circulation.   
There are three types of exhaustions; national, regional and international exhaustion.245  
Article 6 of the TRIPS Agreement states that ‘practices relating to exhaustion cannot be 
challenged under the WTO dispute settlement system.’ The Doha Declaration has 
‘reaffirmed that Members do have the right to establish their own regime for such 
exhaustion without challenge.’ The TRIPS Agreement therefore renders parallel 
importing as an issue for “domestic consideration” and a country has a choice to opt for 
any of the three systems of exhaustion.246  
A system of national exhaustion provides that patent right owner’s distribution rights are 
only considered exhausted until they put the patented item on the market in that 
country.247 Under international exhaustion, a patentee is barred from exercising rights 
over products that have already been put anywhere in the international market. This 
limitation therefore allows countries to import the patented drugs where such drugs 
have already been placed on the market by the patentee anywhere in the world.248 A 
developing country like Botswana is mostly likely to opt for international exhaustion to 
enable it import drugs across the world where they are offered at a cheaper price 
therefore increasing its access to medicine.  
Thus, Section 24 of the Industrial Property Act provides for rights conferred by a patent 
to the patentee. It states that ‘a patent confers the right to prevent third parties from 
exploiting a patent in Botswana without his/her consent and such exploitation includes 
importing the product for purposes of offering it for sell or using it.’249 This section may 
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seem to restrict parallel importing in its entirety. However Section 25 of the Act provides 
for exceptions to rights conferred by a patent. It stipulates that; 
‘this right shall not extend to articles which have been put on the market in 
Botswana or abroad by the patentee or any other person acting with the 
patentee’s consent.’250  
Section 25(1)(a) therefore seeks to override Section 24(2)(a)(ii) and thus suggesting 
that parallel importing is permissible in Botswana and the government can “shop 
around” and get better prices for pharmaceutical products. Botswana seems to follow 
the international exhaustion doctrine as it permits access to the importation of drugs 
available on the international market without the patent holder’s consent provided the 
drugs have been placed on the international market by the patent holder or a person 
acting under the authority of the patent holder.251  
 
v. Exceptions to Patent Rights 
 
Member States are permitted under Article 30 of the TRIPS Agreement to implement 
limited exceptions to the exclusive rights conferred by a patent. These exceptions are 
based on the ground patent rights are not absolute and may be waived where a greater 
public interest arises. Article 30 provides for a three-fold test to be satisfied. It states 
that ‘patent rights must not unreasonably conflict with a normal exploitation of the patent 
and not unreasonably prejudice the legitimate interests of the patent owner, taking 
account of the legitimate interests of third parties.’  
Section 25 of the Industrial Property Act provides for a list of exceptions to patent rights. 
One which is of relevance is that patent rights shall not extend to articles which have 
been put on the market in Botswana or abroad by the patentee or any other patentee’s 
consent.252 One advantage of using this flexibility as a tool to access medicine is that 
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they apply automatically and therefore do not need prior consent of the patent holder or 
other authority. It also does not require that the patent holder be compensated. This is 
one of the flexibility that’s been mostly utilized by the government of Botswana to 
acquire medicines elsewhere once the needed medicine has been already introduced in 
the international market. 
 
vi. Limitations on Data Protection 
 
Article 39.3 of the TRIPS Agreement provides for data protection of test data against 
unfair commercial use. This right may be flexed to allow the timely entrance of generic 
drugs into the market. If the law is to grant exclusive data rights to the patent holder 
then generic companies cannot use such data submitted to produce generic drugs until 
the data exclusivity period ends. Usually, manufacturers of generic drugs rely on the 
use of originator’s test data as it is cumbersome and costly for generic industry to repeat 
the testing process.253 Interestingly, Section 114(4) of the Industrial Property Act 
prohibits the act of unfair competition. It provides that;  
‘when, as a condition of approving the marketing of a pharmaceutical chemical 
product that utilizes new chemical substances requires the submission of 
undisclosed tests or other data, the origination of which involves a considerable 
effort, such data shall be protected against unfair commercial use and disclosure 
and where it is necessary to protect the public, such data shall be disclosed on 
condition that steps are taken to protect it from unfair commercial use.’ 
It further provides that; 
‘…test data shall be considered undisclosed if it is not generally known or readily 
accessible to persons within the circles which it is normally dealt with; it has been 
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subjected to reasonable steps under the circumstances to preserve it from 
disclosure; and it has commercial value because it is secret.’254  
As already stated, Botswana has pharmaceutical manufacturing capability and therefore 
it is difficult for the government to implement this flexibility to enable local manufacturers 
to use the test data in producing generic drugs. 
 
4.3 ACTUAL USAGE OF THE TRIPS FLEXIBILITIES 
 
i. Exclusion from Patentability 
 
On the issue of patentable subject matter, Section 9 of the Industrial Property Act 
excludes from patentability all methods used for treatment of the human body as well as 
diagnostic methods practiced in relation thereto. There has been actual implementation 
of this flexibility in Botswana. For instance, the Botswana Harvard AIDS Institute 
Partnership (BHP) carries out clinical and laboratory researches dealing with HIV 
infections. All diagnostic methods conducted by the Botswana-Harvard HIV Reference 
laboratory cannot be patented and as such HIV/AIDS diagnostic kits cannot be patented 
in Botswana.255 
 
ii. Parallel importing 
 
In the year 2000, the Botswana government declared HIV/AIDS a national emergency 
and launched the Botswana Antiretroviral Therapy (ART) Programme. As such, the 
Government of Botswana went into partnership with pharmaceutical companies and 
began importing generic ARVs from pharmaceuticals companies in India that offered 
discounted pricing despite the existence of the same generic ARVS in the Botswana 
market so as to ensure greater coverage of the ART Programme.256 Recently, the 
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Ministry of Health of Botswana launched the “Treat All” HIV/AIDS strategy campaign 
which aims to ensure that persons that test positive to HIV must receive treatment 
immediately despite their CD4 count as opposed to the old method of reserving 
treatment for those with lower CD4 counts.257  
The Ministry has since then entered into agreement with one of the leading 
pharmaceutical companies ViiV Healthcare for the supply of the dolutegravir drug used 
as a first line treatment in HIV infected persons. The company offers lower prices to 
lower middle income countries like Botswana.258 Consequently, Botswana became the 
first Sub Saharan country to use this drug as part of a national health programme since 
its recommendation by the WHO in the year 2015.259 As such, parallel importing of this 
drug has therefore allowed more HIV infected to have access to the drug which would 
have otherwise been very costly to acquire. 
Zimbabwe on the other hand also follows the international exhaustion of patent rights 
regime and has made actual use of parallel importing. This is permitted under Section 
24A of its Patent Act260. One of the local pharmaceutical companies called Datlabs 
imports cheaper drugs from a pharmaceutical company in India called Ranbaxy.261  
 
iii. Exceptions to patent rights 
 
Section 25 of the Industrial Property Act deals with the exhaustion of patent rights once 
the patented drug has been placed in Botswana’s local or international market by the 
                                                                                                                                                                                                    
Constraints thereon within the Region, available at 
http://www.wipo.int/edocs/mdocs/patent_policy/en/wipo_ip_dur_13/wipo_ip_dur_13_ref_t5a.pdf 
(accessed on 08 October 2016). 
257  World Health Organisation Regional Office for Africa: available at 
http://www.afro.who.int/en/botswana/press-materials/item/8739-botswana-launches-treat-all-
strategy.html, accessed on 10 October 2016. A CD4 count is a laboratory test that measures how 
well one’s immune system is working and the rate of HIV progression (https://www.aids.gov/hiv-aids-
basics/just-diagnosed-with-hiv-aids/.../cd4-count/). 
258 See http://www.gsk.com/en-gb/media/press-releases/2016/viiv-healthcare-announces-public-tender-
agreement-with-botswana-ministry-of-health-for-dolutegravir/, accessed on 10 October 2016. 
259 WHO Policy brief: Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and 
Preventing HIV Infection. Published Nov 2015. Available at http://www.who.int/hiv/pub/arv/policy-
brief-arv-2015/en/, accessed on 10 October 2016. 
260  Chapter 26:03, Laws of Zimbabwe. 
261  Pfumorodze, J ‘The WTO TRIPS Agreement and Access to Medicines in Southern Africa’ (December 
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patent holder or any other person duly authorized. This allows the government of 
Botswana to import drugs without the patent holder’s consent once they have been 
introduced into the market. This is the most utilized flexibility to acquire medicines in 
Botswana since the sale of patented drugs in any part of the world causes exhaustion of 
such rights in Botswana as well. Botswana can therefore freely import such drugs 
without prior consent of the patent holder. Below is a table showing some of the drugs 
imported to Botswana from India in the year 2016.262  















Medicines Rifampicin 60/Isoniazid 30/ Pyrazinamde 150mg 






Medicines Rifampicin 150 Mg /Isoniazid 75 Mg Pyrazinamide 





Drugs & Pharma,Medicines Rifampicin 150mg Isoniazid 75 Mg / 




Drugs & Pharma,Medicines Rifampicin 150mg /Isoniazid 75 Mg 






Drugs & Pharma,Medicines Rifa 60/Iso 30/Pyra 150mg 




Drugs & Pharma,Medicines Rifampicin 150/ Isoniazid 75/ 
Ethambutol 275 Mg Tablets 
38183.46 833000 
 
In comparison, Zimbabwe’s provision on exceptions to patent rights has gone further to 
also incorporate the flexibility on limitation of data protection by providing for early 
working exceptions. Section 24B of the Patent Act provides that ‘test batches of a 
patented product may be produced without the consent of the patentee six months 
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before the expiry of the patent, provided that the test batches shall not be put on the 
market before the expiry date of the patent.’ Consequently, once the test batches have 
been produced, the original term of the patent may not be extended. This has assisted 
its local pharmaceutical companies such as Varichem and Datlabs to use such test data 
prematurely in manufacturing generic versions of drugs.263  
 
iv. Compulsory licensing 
 
Till date no compulsory licenses have been issued by Botswana. 264 The government of 
Botswana has not yet made use of the notification by submitting its intention to the 
TRIPS council to import drugs under the Paragraph 6 system.265  
Under the South African Patents Act,266 compulsory licenses are allowed where there is 
an abuse of patent rights. According to Section 56 of the Act, abuse of patent rights may 
occur in four scenarios. Namely where;  
• ‘the invention is not being worked in South Africa on a commercial scale267 
• the demand for the patented drug is not being met adequately and on reasonable 
terms268 
• the patentee has refused to grant a license on reasonable terms and such refusal 
prejudices the establishment of a new industry or that it is in the public interest 
that a license should be granted269 and 
• the demand for the patented drug is being met by importation and the price 
charged for the patented drug by the patent holder is excessive in relation to the 
price charged in the country of manufacture.’270 
                                                             
263  Pfumorodze, J ‘The WTO TRIPS Agreement and Access to Medicines in Southern Africa’ (December 
2011) 13 University of Botswana Law Journal 99. 
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South Africa therefore seems to have taken a robust position in ensuring that patent 
rights do not unjustifiably inhibits its means of acquiring essential medicines. Its 
compulsory license provisions cater for any eventuality that may act as a stumbling 
block in ensuring South Africa has access to adequate medicine for its citizens.271 In 
2001 South Africa announced that compulsory licenses would be issued on ARVs 
manufactured by GlaxoSmithKline (GSK) and Boehringer Ingelheim (BI).272 On the 
contrary, Prof. Yousuf Vawda in his recent article avers that since 1978, South Africa 
has never issued a compulsory license.273  
Similarly, Zimbabwe has also incorporated TRIPS flexibilities in its Patent Act274 to 
promote access to medicine and has made actual use of the compulsory licensing 
flexibility. Section 35 of Zimbabwe’s Patent Act allows for issuance of compulsory 
licenses by the government during periods of public health emergencies. The 
government of Zimbabwe in May 2002 declared a six months period of public health 
emergency on HIV/AIDS and begun to locally manufacture ARVs by issuing a 
compulsory license to a company called Varichem Pharmaceuticals (Private) Limited.275 
The company later began manufacturing generic versions which lowered the price of 
ARVs from US$1,168 to US$412 per patient per year.276 
Till date several local manufacturing pharmaceutical companies in Zimbabwe have 
been granted compulsory licenses by the government to manufacture and or import 
HIV/AIDS generic drugs.277 Furthermore, the World Health Organisation (WHO) in 2010 
certified that Varichem Pharmaceuticals conforms to international standards and may 
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271  Ndlovu, L Access to Medicines under the World Trade Organization TRIPS Agreement: A 
Comparative Study of Select SADC Countries (unpublished LLD thesis, University of South Africa, 
2014)199-201. 
272 See Knowledge Ecology International’s brief, available at http://keionline.org/misc-
docs/recent_cls_8mar07.Pdf, accessed on 14 October 2016.  
273 ‘Regering hou jou medikasie duur’ Netwerk24, 30 October 2016 available at 
http://www.netwerk24.com/Nuus/Gesondheid/regering-hou-iou-medikasie-duur-20161029, accessed 
on 23 November 2016. 
274   Chapter 26:03, Laws of Zimbabwe. 
275  Ndlovu, L Access to Medicines under the World Trade Organization TRIPS Agreement: A 
Comparative Study of Select SADC Countries (unpublished LLD thesis, University of South Africa, 
2014) 195. 
276  Ibid at 195. 
277  Pfumorodze, J ‘The WTO TRIPS Agreement and Access to Medicines in Southern Africa’ (December 
2011) 13 University of Botswana Law Journal 97. 
65 
 
export its drugs to other countries in the region.278 This is has helped promote the 
availability of ARVs in Zimbabwe and ensuring its citizens are afforded proper health 
care. Other countries in the region may also benefit from this by importing cheaper 
ARVS from Zimbabwe. 
 
v. Government Use of Patents 
 
In 2000 the Government of Botswana went into agreement with the Bill & Melinda Gates 
Foundation and Merck & Co. Inc to establish the African Comprehensive HIV/AIDS 
Partnerships (ACHAP). Under the agreement, Merck & Co. continuously donates two 
anti-retroviral   drugs namely Crixivan (Indinavir) and Stocrin (Efavirenz) to Botswana to 
be used in public hospitals. This could be Botswana’s answer in ensuring that its needy 




The flexibilities enshrined in the TRIPS Agreement seek to diminish the adverse effects 
of intellectual property rights on the cost of medicines and thereby promoting access to 
cheaper medicines. Botswana being a signatory of the TRIPS Agreement has 
domesticated and implemented the TRIPS Agreement in a manner that does not 
completely hinder the right of the country to protect public health and to promote access 
to medicines. It is evident that Botswana has incorporated all the above discussed 
TRIPS flexibilities in its current Industrial Property Act. However, Botswana has up to 
this point not fully utilized most of these flexibilities as a mechanism for ensuring 
adequate access to essential medicines due to its market size and lack of 
pharmaceutical manufacturing companies.  Botswana could learn from countries like 
Zimbabwe and make use of the compulsory licensing flexibility to access cheaper ARVs 
for its people. 
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CONCLUSION AND RECOMMMENDATIONS 
 
5.1 INTRODUCTION  
 
Access to medicine in Botswana is cumbersome. The research has highlighted a 
number of concerning matters in respect of access to medicine in Botswana and the 
TRIPS agreement. The study was guided by the following pertinent objectives;  
• To determine how intellectual property came to be on the trade agenda; 
• To determine how the right to access to health care and intellectual property 
rights are protected in Botswana; 
• To determine the  extent to which TRIPS flexibilities been incorporated in SADC 
countries’ domestic legislations particularly Botswana to advance access to 
medicine; 
• To determine how developing countries can make full use of the TRIPS 
flexibilities without falling foul of the basic tenets of intellectual property law;  and  
lastly 
• To determine what the legal and policy interventions need to be implemented to 
ensure that developing countries fully utilize TRIPS flexibilities.  
 
Now, it is incumbent on this chapter to succinctly discuss these problem areas 
highlighted in the preceding chapters. Thereafter, the chapter will propose 







5.2 ISSUES IDENTIFIED 
 
It was established in chapter one that financial accessibility of medicines is one of the 
ongoing challenges faced by most developing countries.280 Most of the SADC countries 
depend on imported drugs and although pharmaceutical companies attempt to make 
drugs affordable, most patented drugs are very pricy which often lead to affordability 
barriers. Prior to the TRIPS Agreement281 there were no international conventions that 
set out the minimum standards of patent protection but WTO Members are now 
expected to modify their national legislation so as to conform to the minimum standards 
of intellectual property rights protection as set out by the TRIPS Agreement.282 It was 
further established that the pharmaceutical industry has exploited the patent system in a 
way to inhibit access to medicine by poorer countries by making these patented drugs 
unaffordable to them. As discussed, the notorious practice by pharmaceutical 
companies of extending patent life spans beyond the mandatory 20 year period by filing 
for secondary patents is the leading cause of exorbitant drug prices.283 This practice 
elongates the exhaustion period of these patents therefore making it impossible for 
other pharmaceuticals to produce generic versions of the patented drugs.284  
 
As an outcry to the over pricing of patented drugs, TRIPS flexibilities were included in 
the Agreement. Thus, developing countries may avail themselves to TRIPS flexibilities 
to avoid patent protections and have access to generic drugs.285 According to the MDG 
reports, improved access to medicines in poor countries has led to the decline of most 
avoidable deaths.286 For instance deaths of children under 5 years of age as a result of 
measles has declined rapidly since 2000, from 544,200 deaths to 145,700 deaths in 
2013.287 It is therefore evident that poor access to medicines continues to be the leading 
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cause of deaths in most developing countries. Botswana, for example being a 
landlocked country and having limited market size does not have any pharmaceutical 
manufacturing capacity. Despite the continued injection of more money into the heath 
sector to continue meeting the health needs of its people, the country is still reliant on 
imported drugs which are mostly patented drugs in order to meet the needs of its 
people.288 Thus, it reviewed its IP laws to include the TRIPS flexibilities. As such, the 
study sought to establish the extent to which TRIPS flexibilities have been incorporated 
in Botswana’s national legislation and found that Botswana has incorporated most of the 
TRIPS flexibilities in its Industrial Property Act.289 The study also sought to examine the 
technical barriers in trade that are preventing Botswana from fully utilizing these TRIPS 
flexibilities in order to promote access to cheaper medicines and found lack of 
pharmaceutical manufacturing capacity to be the leading setback.290  
Further, the discussion regarding the historical development of intellectual property in 
international trade (in chapter 2), the protection of intellectual property rights in 
international trade has been characterised with different phases of development. The 
initial phase is characterised with the absence of the international protection of 
intellectual property rights.291 It was only towards the end of the 19th century that states 
began to take a greater interest in the possibility of international co-operation on 
intellectual property matters.292 It was established that despite the Paris Convention for 
the protection of Industrial Property (1883) whose aim was to harmonize patent laws 
and regulations as stipulated by various countries, developing countries were reluctant 
to ratify the Paris Convention due to the fear that no technical assistance would be 
afforded to them in as far as implementing treaty obligations are concerned.293 One of 
the setbacks of the Convention was its failure to outline minimum standards for patent 
protection to which its Members must adhere.294 The level of intellectual property rights 
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protection to be implemented was left to left to domestic legislation and courts to 
develop.295  
The Berne Convention of 1886 was the cornerstone of international copyright law. The 
Convention miserably failed to establish extensive legal remedies which could be 
enforced by the copyright holders against the copyright infringers.296 It was further 
established in the chapter that the General Agreement on Tariffs and Trade (GATT 
1947) came about at the end of World War II. After World War 1, states had begun to 
conclude unfair trade arrangements for their own political agendas which led to the 
destruction of the multilateral trading system that existed prior to the war. The GATT 
was therefore established as the custodian and enforcer of free trade in the multilateral 
trading system.297 Despite the fact that the first seven rounds of GATT negotiations 
mostly dealt with tariff reductions, intellectual property rights were not completely foreign 
to the GATT before they were tabled for negotiation during the Uruguay Round.298 
Ultimately, this final GATT round marked the birth of the World Trade Organisation 
(WTO). In contrast, to the WTO, the GATT considered intellectual property matters to 
be “internal” matters that resonated between States in their private dealings.299 
 
The advent of the TRIPS Agreement (an agreement administered under the WTO) 
marked the beginning of an evolution in as far as globalizing of intellectual property 
rights is concerned.300 To most developing countries, the establishment of the TRIPS 
Agreement entailed a great deal of reform to their domestic legislation in as far as 
intellectual property rights were concerned thus they were reluctant to sign the TRIPS 
Agreement due to fear of the economic implications as the Agreement would forestall 
access to new technologies leading to higher prices especially in pharmaceuticals.301 It 
was discussed that in order to address these concerns, the TRIPS gave Member States 
flexibilities which allowed states for example to disregard TRIPS obligations for national 
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concerns such as health issues in implanting their domestic intellectual property 
regimes. Despite this, the TRIPS Agreement has led to an increase in the formation of 
free trade agreements that seek to implement intellectual property standards set out in 
the TRIPS Agreement.302 Consequently, while developing countries are still struggling 
to conform to the standards set out by the TRIPS, developed countries continue to 
strengthen intellectual property rights through free trade agreements. However, due to 
the increased preference of free trade agreements over multilateral agreements, 
developing countries are not hesitant to trade off intellectual property rights in order to 
gain market access for agricultural goods in these free trade agreements.303 Issues of 
intellectual property rights have therefore transitioned from being issues of national 
consideration to having a status of a core obligation in the international trading system. 
 
Having established the effect of TRIPS on developing countries, chapter three assessed 
the legal framework of Botswana particularly how human rights and intellectual property 
rights are protected and found that the Constitution of Botswana has no express 
provision to the right to health. The Constitution only allows for other rights to be 
disregarded for the protection of public health.304Due to this finding, the chapter 
examined international instruments such as the Universal Declaration of Human 
Rights (UDHR) and the International Covenant on Economic, Social and Cultural Rights 
(ICESCR) to establish whether public health was a facet to the right to health.305 It was 
established that the right to health is not confined to health care alone but extends to 
conditions pertinent to good health such as housing, a healthy environment and access 
to safe and potable water. Therefore, the Constitution of Botswana does not address 
the issue of health care through ensuring access to medicine but is rather more focused 
on the social well-being aspect of the right to health.306 In comparison to Botswana, 
South Africa and Zimbabwe have incorporated health care provisions in their 
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Constitutions.307 Lack of constitutional protection of the right to health care in Botswana 
therefore burdens the courts and other non-state actors with the onerous task of 
enforcing this indistinct right.308 
 
The chapter also explored the various Non-governmental Organizations (NGOs) in 
Botswana that seek to protect and promote human rights and intellectual property rights 
and identified them to be the key players in raising public awareness of the various 
human rights that are provided for in the Constitution of Botswana. These NGOs also 
exist to provide health and social services to the community as a way of promoting 
proper health care.309 
Further, the research found that Botswana has only two pieces of legislation that deal 
with intellectual property rights, that is; the Copyright and Neighbouring Rights Act and 
the Industrial Property Act and found that the Copyright and Neighbouring Rights Act 
deals with the protection of the rights of artists, authors and creators, as well as the 
protection of their literary and artistic work whereas the Industrial Property Act deals 
with trademarks, industrial designs, utility models and patents.310 It was also found that 
the Companies and Intellectual Property Authority is a parastatal which is regarded as 
the formal tool for intellectual property rights management in Botswana. The body is 
tasked with the registration of trade marks, industrial designs and the granting of patent 
certificates. The body is also responsible for combating copyright infringement and 
piracy in Botswana.311 
As such, chapter four explored the various TRIPS flexibilities that have been 
domesticated into Botswana’s Industrial Property Act and discussed the extent to which 
such flexibilities have actually been utilized by the government of Botswana in order to 
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improve access to medicine.312 The findings of this chapter may be summarized as 
follows; 
• Botswana being a signatory of the TRIPS Agreement has domesticated and 
implemented the TRIPS Agreement in a manner that does not completely hinder 
the right of the country to protect public health and to promote access to 
medicines; and 
•  Botswana has incorporated various TRIPS flexibilities in its current Industrial 
Property Act namely; exception to patent rights, exclusion from patentability, 
compulsory licensing, paragraph 6 system, parallel importing, public non-
commercial use of patents (government use) and limitations on data 
protection.313 
 
However, Botswana has up to this point not fully utilized most of these flexibilities as a 
mechanism for ensuring adequate access to essential medicines due to its market size 
and lack of pharmaceutical manufacturing companies. It has also been established that 
Botswana has not yet submitted its intention to the TRIPS Council to make use of the 
Paragraph 6 system which could be its gateway to improving its access to cheaper 
medicines.314 The introduction of the waiver under the TRIPS Agreement allowing the 
importation and exportation of drugs manufactured under compulsory licensing should 
have been Botswana’s loophole to allow foreign pharmaceutical companies to 
manufacture drugs on behalf of Botswana. This has been noted as Botswana’s major 
weakness in as far as promoting access to medicine is concerned. However, the 
chapter noted in contrast that Zimbabwe has utilized the compulsory licensing flexibility 
in the production of ARVs which has consequently been beneficial to the SADC region 
at large.315 The position of South Africa regarding actual issuance of compulsory 
licenses is unclear. However, South Africa awards a higher percentage of 
pharmaceutical patents than western countries, even USA and European states, due to 
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it not having a patent inspection system which consequently results in numerous 




Having identified the above issues, this chapter will now make particular 
recommendations on how Botswana can make full use of the TRIPS flexibilities 
incorporated in the Industrial Property Act thereby further promoting access to medicine. 
These recommendations are made upon a critical analysis on how its neighboring 
countries such as South Africa and Zimbabwe have taken advantage of these 
flexibilities to promote local production of medicines and improving access to medicine 
in general. 
 
5.3.1 Establishing local pharmaceutical manufacturing companies 
 
One of the main reasons why Botswana has not fully utilized the TRIPS flexibilities is 
due to lack of pharmaceutical manufacturing capacity. Encouraging local production of 
drugs will massively lower the cost of importing drugs from countries such as India and 
South Africa. This is because it is cheaper to import raw materials used in 
manufacturing drugs than the finished drugs themselves. Locally manufacturing drugs 
will not only improve access to medicine in Botswana alone as this will also stimulate 
export to other countries in the region.317  
Furthermore, establishing local pharmaceutical companies will enable Botswana to 
make full use of other flexibilities such as limitation on test data. Section 114(4) of the 
Industrial Property Act provides that test data of a new drug may be disclosed where 
such data is in the public health interest. The use of such test data will allow for timely 
manufacturing of generic drugs in Botswana. This is because manufacturers of generic 
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drugs rely on the use of originator’s test data as it is cumbersome for the generic 
industry to repeat the testing process.318 
 
5.3.2 Submit intention to make use of Paragraph 6 system under Article 31bis of 
the TRIPS Agreement 
 
In order to import drugs under the Paragraph 6 system, Paragraph 1(b) of the Annex to 
the TRIPS Agreement requires Member States to notify the TRIPS Council of its 
intention to use the system. Previously, drugs manufactured under compulsory licensing 
were to be predominantly for the supply of the domestic market.319 This created a 
barrier for developing countries with no pharmaceutical manufacturing capacity. With 
the introduction of the Paragraph 6 system, developing countries may issue compulsory 
licenses to foreign pharmaceutical companies to manufacture drugs on their behalf. As 
noted above, Botswana is a qualifying member but has however not utilized this waiver 
in order to have access to cheaper drugs. Consequently, unlike Zimbabwe, Botswana 
cannot take advantage of the compulsory licensing flexibility to use foreign 
pharmaceutical companies to manufacture the ARVs that it undeniably needs. 
 
5.3.3 Amendment of Botswana’s competition laws to extend to intellectual 
property rights 
 
The TRIPS Agreement permits countries to implement competition-based exceptions to 
patent rights. Botswana’s competition laws do not address the issue of intellectual 
property rights particularly patent rights. Such competition laws would serve as a 
deterrent to abuse of patent rights in Botswana. Therefore Botswana’s Competition Act 
of 2009320 would be the ideal piece of legislation to address the issue of abuse of patent 
rights. A lesson could be drawn from South Africa’s inclusion of competition law as a 
TRIPS flexibility to facilitate access to medicine. Section 8(a) of the South African 
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Competition Act321 prohibits the abuse of dominance by stipulating that a dominant firm 
shall not charge excessive prices to the detriment of consumers. As demonstrated by 
case law, the aforementioned provision has positively advanced access to medicine by 
ensuring that pharmaceutical companies do not unreasonably charge high prices for 
drugs.  
In the case of Hazel Tau and Others v GlaxoSmithKline and Boehringer Ingelheim,322 
the applicants, Treatment Action Campaign (TAC)323 acting on behalf of HIV patients 
and medical professionals filed a complaint to the Competition Commission alleging that 
Boehringer Ingelheim and GlaxoSmithKline charged excessive prices for ARVs which is 
in contravention of Section 8(a) of the Competition Act.324 The Applicant further alleged 
that the exorbitant prices of ARVs led to deaths of people living with HIV/AIDS due to 
being unable to afford the drugs. The allegations were investigated by the Competition 
Commission and it was subsequently held that the two pharmaceutical companies had 
abused their dominant position in the market by charging exorbitant prices for their 
drugs and denying other pharmaceutical companies to manufacture generic versions of 
their patented drugs for a reasonable royalty.325 Consequently, the two companies 
agreed to allow the manufacture of generic versions of their drugs by selected 
pharmaceutical companies. For the first time, generic drugs were now commercially 
available in South Africa.326  
Further, in Treatment Action Campaign v Bristol-Myers Squibb327, the AIDS Law Project 
(ALP) in 2005 acting on behalf of Treatment Action Campaign lodged a complaint that 
Bristol-Myers was over pricing an anti-fungal medicine which was mostly used to treat 
HIV/AIDS related fungal infections. The patent rights of the drug in question had expired 
but the company still enjoyed monopoly over the drug and generic versions of it were 
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not available in South Africa.328 According to the complainants, a generic version of the 
drug was available in Brazil and was being sold at a fraction of the price of the drug in 
South Africa. Consequently, Bristol-Myers agreed to lower the price of its anti-fungal 
medicine.329   
Based on the example of South African case law, it can be argued that competition laws 
may be the best watchdog against abuse of patent rights in developing countries 
particularly where the government is unwilling to act.330 The Botswana government 
could therefore amend its competition laws to extend to patent rights so as to ensure 
prices of drugs in its local market are not exorbitant.  
 
5.3.4 Judicial strategy 
 
Due to the absence of an express provision promoting access to medicine in Botswana, 
the courts should step in and clarify the nature and scope of “public health”. Public 
health cannot be achieved where access to essential medicine is not protected by the 
law. Having the right to access to medicine as a facet of the greater right to health will 
ensure that the government accords utmost attention to implementing health policies 
that address the health needs of the people in Botswana. This is because any 
omissions in protecting the right may be challenged in the courts of law. Non-
Governmental Organizations (NGOs) or private individuals may therefore bring actions 
to the courts of Botswana challenging violation of their right to access to medicine.331 
For instance, Section 27 of the South African Constitution entitles citizens to challenge 
their right to have access to health care services as was illustrated in the case of 
Soobramoney v Minister of Health (KwaZulu-Natal).332 In this case, Mr Soobramoney 
who was suffering from a chronic kidney failure was denied access to dialysis machine 
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for not satisfying the medical criteria that he was illegible for a kidney transplant.333 He 
applied to the Court challenging the infringement of two of his basic Constitutional rights 
being the right to life334 and the right not to be denied of emergency medical 
treatment.335The Constitutional Court dismissed the claim on the ground that his failure 
to meet the criteria did not constitute a violation of his rights as the state’s limited 
resources could not cater for everyone.336 The Constitutional Court further held that his 
condition was not a medical emergency as it was an ongoing state of affairs.337 
Although the case was dismissed, the court rose to the occasion to elucidate on what 
“emergency medical treatment” in terms of Section 27(3) of the Constitution entails.338 It 
held that the right to emergency medical treatment meant that an individual who suffers 
a sudden catastrophe that necessitates speedy medical attention should not be denied 
such treatment from a hospital equipped to administer the necessary treatment. 
Similarly, in the case of Minister of Health and others v Treatment Action Campaign,339 
Treatment Action Campaign brought an action against the Minister of Health for not 
ensuring that drugs that prevent mother-to-child transmission of HIV called Nevirapine 
are widely available to the population.340 In light of Section 27 of the Constitution, the 
court found that the government had infringed Section 27 since doctors at public 
hospitals and clinics were not allowed to prescribe the drug even where it was medically 
indicated. Furthermore, only medical practitioners at research and training sites could 




From the findings of this study, it is clear that incorporating TRIPS flexibilities into the 
national legislation does not automatically yield better access to medicine. As already 
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334  Section 11 
335  Section 27(3) 
336  At 777 par 20. 
337  At 774 par 21. 
338  At 774 par 20. 
339  2002 (5) SA 721 (CC). 
340  Supra at 731 par F-H. 
341  Supra at 765 par C-D. 
78 
 
discussed, there is need to change economic and political framework of the country in 
order for a country to fully utilize these flexibilities. The government of Botswana took a 
step in the right direction by incorporating the TRIPS flexibilities in its Industrial Property 
Act. However, it is clear from the findings of this study that despite having incorporated 
these flexibilities, Botswana has up to date been unable to fully utilize them. This has 
mostly been attributed to economic factors such as Botswana’s small market size and 
the lack of pharmaceutical manufacturing capacity. Therefore, the recommendations 
suggested can only be effective in improving access to cheaper medicine if Botswana 
amends its laws and policies relating to access to medicine and implements all other 
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